Document:

EX-10.3

 Exhibit 10.3 
 IROKO PHARMACEUTICALS INC. 
 NOTICE OF GRANT OF SHARE OPTION

 Notice is hereby given of the following option grant (the “Option”) to purchase Ordinary Shares
of Iroko Pharmaceuticals Inc. (the “Company”): 
 Optionee:
                                         
                                         
                    

Grant Date:
                                         
                                         
                 
 Vesting Commencement
Date:
                                         
                            
 Exercise Price:
                             per Ordinary Share 

Number of Option Shares:
                                 Option Shares 

Expiration Date:
                                         
                            
 Type of Option:              Incentive Share Option (ISO) 

                 Non-statutory Share Option (NSO)

 Date Exercisable: The Option shall become exercisable with respect to the Option Shares as follows: 

Seventy percent (70%) of the Option Shares shall vest and become exercisable over a four (4) year period in equal annual
installments, measured from the Vesting Commencement Date. The remaining thirty percent (30%) of the Option Shares shall vest and become exercisable upon the earlier of (i) the nine year anniversary of the Vesting Commencement Date,
(ii) a Change of Control, or (iii) an initial public offering of equity securities of the Company to investors on a public stock exchange (an “IPO”). 

Notwithstanding the foregoing, the Option shall become fully vested and exercisable for all the Option Shares (vested and unvested) upon
the earlier of a Change of Control or an IPO. However, in the event of Optionee’s cessation of Service for any reason, Optionee shall not be entitled to any additional Option Shares other than those Option Shares which have vested in accordance
with the above schedule, unless specifically authorized by the Plan Administrator, in its sole discretion, pursuant to an express written agreement with Optionee. 
 Optionee understands and agrees that the Option is granted subject to and in accordance with the terms of the Iroko Pharmaceuticals Inc. Amended and Restated 2012 Share Option/Share Issuance Plan (the
“Plan”). Optionee further agrees to be bound by the terms of the Plan and the terms of the Option as set forth in the Share Option Agreement attached hereto as Exhibit A. Optionee hereby acknowledges receipt of
a copy of the Plan in the form attached hereto as Exhibit B. Notwithstanding the foregoing, to the extent there are any inconsistencies between the terms and conditions under which the Option becomes fully vested and exercisable, the
terms and conditions set forth in this Notice shall govern. 

 RESTRICTIONS ON OPTION SHARES. OPTIONEE UNDERSTANDS THAT ALL OPTION SHARES
ACQUIRED UPON THE EXERCISE OF THE OPTION SHALL BE SUBJECT TO CERTAIN RESTRICTIONS AND RIGHTS AS SPECIFIED IN THE ATTACHED SHARE PURCHASE AGREEMENT. 
 At Will Employment. Nothing in this Notice or in the attached Share Option Agreement or Plan shall confer upon Optionee any right to continue in Service for any period of specific duration
or interfere with or otherwise restrict in any way the rights of the Company (or any Parent or Subsidiary employing or retaining Optionee) or of Optionee, which rights are hereby expressly reserved by each, to terminate Optionee’s Service at
any time for any reason, with or without cause. 
 Definitions. All capitalized terms in this Notice shall have
the meaning assigned to them in this Notice or in the attached Share Option Agreement. 
 [SIGNATURE
PAGE FOLLOWS] 

  
 2 

 DATED:
                                         
       ,                  

 

			
	IROKO PHARMACEUTICALS INC.
		
	By:	 	 
		
	Title:	 	 
	
	 

  

			
	OPTIONEE
		
		 	 
		 	(Signature)
		
		 	 
		 	(Print Name)
		
	Address:	 	 
		
		 	 

 Attachments: 
 Exhibit A – Share Option Agreement 
 Exhibit B – Amended and Restated 2012
Share Option/Share Issuance Plan 
 Exhibit C – Share Purchase Agreement 

  
 3 

 EXHIBIT A 

SHARE OPTION AGREEMENT 
 IROKO PHARMACEUTICALS INC. 
 INCENTIVE SHARE OPTION AGREEMENT

 RECITALS 
 A. The Board has adopted the Plan for the purpose of retaining the services of selected Employees, non-Employee members of the Board or the board of directors of any Parent or Subsidiary and consultants
and other independent advisors in the service of the Company (or any Parent or Subsidiary). 
 B. Optionee is to render valuable
services to the Company (or a Parent or Subsidiary), and this Agreement is executed pursuant to, and is intended to carry out the purposes of, the Plan in connection with the Company’s grant of an option (this “Option”)
to Optionee. 
 C. All capitalized terms in this Agreement shall have the meaning assigned to them in the attached Appendix.

 AGREEMENT 
 NOW, THEREFORE, it is hereby agreed as follows: 
 1. Grant of
Option. The Company hereby grants to Optionee, as of the Grant Date, an option to purchase up to the number of Option Shares specified in the Grant Notice. The Option Shares shall be purchasable from time to time during the Option term
specified in Section 2 at the Exercise Price. 
 2. Option Term. This Option shall have a term of ten
(10) years measured from the Grant Date and shall accordingly expire at the close of business on the Expiration Date, unless sooner terminated in accordance with Section 5. 

3. Limited Transferability. 
 (a) This Option shall be neither transferable nor assignable by Optionee other than by will or the laws of inheritance following Optionee’s death and may be exercised, during Optionee’s
lifetime, only by Optionee. 
 (b) Prior to the date the Company first becomes subject to the reporting requirements of
Section 13 or 15(d) of the 1934 Act, this option, together with the underlying unexercised Option Shares, shall not be the subject of any short position, put equivalent position (as such term is defined in Rule 16a-1(h) under the 1934 Act) or
call equivalent position (as such term is defined Rule 16a-1(b) of the 1934 Act). 

  
 -1-

 (c) Except as otherwise provided in Paragraph 3(a), until the date the Company first becomes
subject to the reporting requirements of Section 13 or 15(d) of the 1934 Act, this option, together with the underlying unexercised Option Shares, shall not be the subject of any pledges, gifts, hypothecations or other transfers, other than
pursuant to the Company’s repurchase rights or in connection with a Change in Control in which this option, together with all other options outstanding under the Plan at such time, shall terminate and cease to be outstanding. 

4. Dates of Vesting and Exercise. This Option shall become vested and exercisable for the Option Shares in one or more
installments as specified in the Grant Notice. As the Option becomes vested and exercisable for such installments, those installments shall accumulate, and the Option shall remain exercisable for the accumulated installments until the Expiration
Date or sooner termination of the Option term under Section 5. 
 5. Cessation of Service. The Option
term specified in Section 2 shall terminate (and this Option shall cease to be outstanding) prior to the Expiration Date should any of the following provisions become applicable: 

(a) Should Optionee cease to remain in Service for any reason (other than death, Disability or Misconduct) while this Option is
outstanding, then Optionee (or any person or persons to whom this Option is transferred pursuant to a permitted transfer under Section 3) shall have a period of three (3) months (commencing with the date of such cessation of
Service) during which to exercise this Option, but in no event shall this Option be exercisable at any time after the Expiration Date. 
 (b) Should Optionee die while this Option is outstanding, then the personal representative of Optionee’s estate or the person or persons to whom the Option is transferred pursuant to Optionee’s
will or the laws of inheritance following Optionee’s death or, if applicable, the person to whom the Option is transferred during Optionee’s lifetime pursuant to a permitted transfer under Section 3 shall have the right to
exercise this Option. Any such right to exercise this Option shall lapse, and this Option shall cease to be outstanding, upon the earlier of (i) the expiration of the twelve (12)-month period measured from the date of Optionee’s death or
(ii) the Expiration Date. 
 (c) Should Optionee cease Service by reason of Disability while this Option is outstanding,
then Optionee (or any person or persons to whom this Option is transferred pursuant to a permitted transfer under Section 3) shall have a period of twelve (12) months (commencing with the date of such cessation of Service) during
which to exercise this Option. In no event shall this Option be exercisable at any time after the Expiration Date. 
 (d) During
the limited period of post-Service exercisability, this Option may not be exercised in the aggregate for more than the number of Option Shares for which this Option is, at the time of Optionee’s cessation of Service, exercisable. The Option
shall not become exercisable for any additional Option Shares, except to the extent (if any) specifically authorized by the Plan Administrator pursuant to an express written agreement with the Optionee. Upon the expiration of such limited exercise
period or (if earlier) upon the Expiration Date, this Option shall terminate and cease to be outstanding for any Option Shares for which the Option has not been exercised. 

  
 -2-

 (e) Should Optionee’s Service be terminated for Misconduct or should Optionee otherwise
engage in Misconduct while this Option is outstanding, then this Option (for all vested and unvested Option Shares) shall terminate immediately and cease to remain outstanding. 

6. Adjustment in Option Shares. In the event of any of the following transactions affecting the outstanding Ordinary Shares
as a class without the Company’s receipt of consideration: any share split, share dividend, spin-off transaction, extraordinary distribution (whether in cash, securities or other property), recapitalization, combination of shares, exchange of
shares or other similar transaction affecting the Ordinary Shares without the Company’s receipt of consideration, then equitable adjustments shall be made to (i) the total number and/or class of securities subject to this Option; and
(ii) the Exercise Price. The adjustments shall be made by the Plan Administrator in such manner as the Plan Administrator deems appropriate in order to reflect such change and thereby preclude a dilution or enlargement of benefits hereunder.

 7. Shareholder Rights. The holder of this Option shall not have any shareholder rights with respect to the
Option Shares until such person shall (having exercised the Option and paid the Exercise Price) have been entered in the Company’s register of members as the record holder of the purchased shares. 

8. Manner of Exercising Option. 
 (a) Except as may be permitted by the Plan Administrator or in the event of a cessation of Service by Optionee in accordance with Section 5, this Option may only be exercised on
March 31, July 31 and December 31 of each year. 
 (b) In order to exercise this Option with respect to all
or any part of the Option Shares for which this Option is at the time exercisable, Optionee (or any other person or persons exercising the Option) must take the following actions: 

(i) Optionee shall execute and deliver to the Company a Purchase Agreement for the Option Shares for which the Option is
exercised. 
 (ii) Pay the aggregate Exercise Price for the purchased shares in one or more of the following
forms: 
 (A) cash or personal or cashier’s check made payable to the Company; 

(B) a promissory note payable to the company, but only to the extent authorized by the Plan Administrator in accordance
with Section 16; or 

  
 -3-

 (C) Should the Ordinary Shares be listed for trading on any stock exchange
at the time the Option is exercised, then the Exercise Price may also be paid as follows: 
 i) in Ordinary
Shares valued at Fair Market Value on the Exercise Date and held by Optionee (or any other person or persons exercising the Option) for the period (if any) necessary to avoid a charge to the Company’s earnings for financial reporting purposes;
provided, however, that to the extent required by applicable law Optionee shall be required to pay to the Company an amount in cash equal to at least the aggregate par value for the Option Shares for which the Option is exercised, or

 ii) to the extent established by the Company and permitted by the Plan Administrator with respect to the
Optionee, through a special sale and remittance procedure pursuant to which Optionee (or any other person or persons exercising the option) shall concurrently provide irrevocable instructions (a) to a brokerage firm (reasonably satisfactory to
the Company for purposes of administering such procedure in compliance with any applicable pre-clearance or pre-notification requirements) to effect the immediate sale of the purchased shares and remit to the Company, out of the sale proceeds
available on the settlement date, sufficient funds to cover the aggregate Exercise Price payable for the purchased shares plus all applicable income and employment taxes required to be withheld by the Company by reason of such exercise and
(b) to the Company to deliver the certificates for the purchased shares directly to such brokerage firm on such settlement date in order to complete the sale; and 

Except to the extent such cashless exercise procedure is utilized in connection with the Option exercise, payment of the
Exercise Price must accompany the Purchase Agreement delivered to the Company in connection with the Option exercise. 
 (iii) Furnish to the Company appropriate documentation that the person or persons exercising the Option (if other than Optionee) have the right to exercise this Option. 

(iv) Execute and deliver to the Company such written representations as may be requested by the Company in order for it
to comply with the applicable requirements of applicable securities laws. 
 (v) Make appropriate arrangements
with the Company (or Parent or Subsidiary employing or retaining Optionee) for the satisfaction of all applicable income and employment tax withholding requirements applicable to the Option exercise. 

  
 -4-

 (vi) Execute and deliver any additional documents reasonably requested by
the Company to effect the exercise of this Option in accordance with this Agreement. 
 (c) As soon as practical after the
Exercise Date, the Company shall issue a certificate for Such Option Shares to Optionee. 
 (d) In no event may this Option be
exercised for any fractional shares. 
 9. Compliance with Laws and Regulations. 

(a) The exercise of this Option and the issuance of the Option Shares upon such exercise shall be subject to compliance by the Company
and Optionee with all applicable requirements of law relating thereto and with all applicable regulations of any stock exchange on which the Option Shares may be listed for trading at the time of such exercise and issuance. 

(b) The inability of the Company to obtain approval from any regulatory body having authority deemed by the Company to be necessary to
the lawful issuance and sale of any Ordinary Shares pursuant to this Option shall relieve the Company of any liability with respect to the non-issuance or sale of the Ordinary Shares as to which such approval shall not have been obtained. The
Company, however, shall use its best efforts to obtain all such approvals. 
 10. Successors and Assigns. Except
to the extent otherwise provided in Section 3, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the Company and its successors and assigns and Optionee, Optionee’s assigns and the legal
representatives, heirs and legatees of Optionee’s estate. 
 11. Notices. Any notice required to be given or
delivered to the Company under the terms of this Agreement shall be in writing and addressed to the Company at its principal corporate offices. Any notice required to be given or delivered to Optionee shall be in writing and addressed to Optionee at
the address indicated below Optionee’s signature line on the Grant Notice. All notices shall be deemed effective upon personal delivery, upon deposit in the U.S. mail, postage prepaid and properly addressed to the party to be notified, or upon
electronic transmittal with confirmation of receipt of such transmittal. 
 12. Construction. This Agreement and
the Option evidenced hereby are made and granted pursuant to the Plan and are in all respects limited by and subject to the terms of the Plan. All decisions of the Plan Administrator with respect to any question or issue arising under the Plan or
this Agreement shall be conclusive and binding on all persons having an interest in this Option. 
 13. Governing
Law. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of the State of Delaware without resort to that state’s conflict-of-laws rules. 

14. Shareholder Approval. If the Option Shares covered by this Agreement exceed, as of the Grant Date, the number of Option
Shares which may be issued under the Plan as last approved by the shareholders, then this Option shall be void with respect to such excess shares, unless shareholder approval of an amendment sufficiently increasing the number of Option Shares
issuable under the Plan is obtained in accordance with the provisions of the Plan. 

  
 -5-

 15. Additional Terms Applicable to an Incentive Option. The following terms
and conditions shall also apply to the grant: 
 (a) This Option shall cease to qualify for favorable tax treatment as an
Incentive Option if (and to the extent) this Option is exercised for one or more Option Shares (i) more than three (3) months after the date Optionee ceases to be an Employee for any reason other than death or Disability; or (ii) more
than twelve (12) months after the date Optionee ceases to be an Employee by reason of Disability. 
 (b) No installment
under this Option shall qualify for favorable tax treatment as an Incentive Option if (and to the extent) the aggregate hair Market Value (determined at the Grant Date) of the Ordinary Shares for which such installment first becomes exercisable
hereunder would, when added to the aggregate value (determined as of the respective date or dates of grant) of any earlier installments of the Ordinary Shares and any other securities for which this Option or any other Incentive Options granted to
Optionee prior to the Grant Date (whether under the Plan or any other Option plan of the Company or any Parent or Subsidiary) first become exercisable during the same calendar year, exceed One Hundred Thousand Dollars ($100,000) in the aggregate.
Should such One Hundred Thousand Dollar ($100,000) limitation be exceeded in any calendar year, this Option shall nevertheless become exercisable for the excess shares in such calendar year as a Non Statutory Option. 

(c) Should Optionee hold, in addition to this Option, one or more other options to purchase Ordinary Shares which become exercisable for
the first time in the same calendar year as this Option, then for purposes of the foregoing limitations on the exercisability of such options as Incentive Options, this Option and each of those other options shall be deemed to become first
exercisable in that calendar year on the basis of the chronological order in which they were granted, except to the extent otherwise provided under applicable law or regulation. 

16. Financing. The Plan Administrator may, in its absolute discretion and without any obligation to do so, permit Optionee
to pay the Exercise Price for the purchased Option Shares by delivering a full-recourse promissory note bearing interest at a market rate and secured by those Option Shares. The payment schedule in effect for any such promissory note shall be
established by the Plan Administrator in its sole discretion. 

  
 -6-

 APPENDIX 
 The following definitions shall be in effect under the Agreement: 

“Agreement” shall mean this Incentive Share Option Agreement. 

“Board’ shall mean the Company’s Board of Directors. 

“Change in Control” shall have the meaning provided to such term in the Plan. 

“Code” shall mean the U.S. Internal Revenue Code of 1986, as amended. 

“Company” shall mean Iroko Pharmaceuticals Inc., a company incorporated under the laws of the British Virgin
Islands and any successor corporation to all or substantially all of the assets or voting shares of Iroko Pharmaceuticals Inc. which shall by appropriate action assume this Option. 

“Disability” shall mean the inability of Optionee to engage in any substantial gainful activity by reason of any
medically determinable physical or mental impairment which is expected to result in death or has lasted or can be expected to last for a continuous period of twelve (l2) months or more. 

“Employee” shall mean an individual who is in the employ of the Company (or any Parent or Subsidiary), subject to
the control and direction of the employer entity as to both the work to be performed and the manner and method of performance. 

“Exercise Date” shall mean the date on which the Option shall have been exercised in accordance with
Section 8 of the Agreement. 
 “Exercise Price” shall mean the exercise price payable per
Option Share as specified in the Grant Notice. 
 “Expiration Date” shall mean the date on which the
Option expires as specified in the Grant Notice. 
 “Fair Market Value” per Option Share on any relevant
date shall be determined in accordance with the following provisions: 
 (i) If the Option Share is at the time
traded on a national market including the Nasdaq Global or Global Select Market, then the Fair Market Value shall be the closing selling price per share on the date in question, as such price is reported by such market and published in The Wall
Street Journal or such other source as the Plan Administration deems appropriate. If there is no closing selling price for the Option Shares on the date in question, then the Fair Market Value shall be the closing selling price on the last
preceding date for which such quotation exists. 

  
 1 

 (ii) If the Option Share is at the time listed on any stock exchange, then
the Fair Market Value shall be the closing selling price per Option Share on the date in question on the stock exchange determined by the Plan Administrator to be the primary market for the Option Share, as such price is officially quoted in the
composite tape of transactions on such exchange and published in The Wall Street Journal or such other source as the Plan Administrator deems appropriate. If there is no closing selling price for the Option Share on the date in question, then
the Fair Market Value shall be the closing selling price on the last preceding date for which such quotation exists. 
 (iii) If the Option Share is not at the time listed on any national market or stock exchange, then the Fair Market Value shall be determined by the Plan Administrator after taking into account such
factors as the Plan Administrator shall deem appropriate but shall in no event be less than the par value of the Option Shares. 

“Grant Date” shall mean the date of grant of the Option as specified in the Grant Notice. 

“Grant Notice” shall mean the Notice of Grant of Share Option accompanying the Agreement, pursuant to which
Optionee has been informed of the basic terms of the Option evidenced hereby. 
 “Incentive Option”
shall mean an option which satisfies the requirements of Code Section 422. 
 “IPO” shall mean an
initial public offering of equity securities of the Company to investors on a public stock exchange. 

“Misconduct” shall mean the commission of any act of fraud, embezzlement or dishonesty by Optionee, any
unauthorized use or disclosure by Optionee of confidential information or trade secrets of the Company (or any Parent or Subsidiary), or any other intentional misconduct by Optionee adversely affecting the business or affairs of the Company (or any
Parent or Subsidiary) in a material manner. The foregoing definition shall not in any way preclude or restrict the right of the Company (or any Parent or Subsidiary) to discharge or dismiss Optionee or any other person in the Service of the Company
(or any Parent or Subsidiary) for any other acts or omissions, but such other acts or omissions shall not be deemed, for purposes of the Plan or this Agreement, to constitute grounds for termination for Misconduct. 

“1934 Act” shall mean the Securities Exchange Act of 1934, as amended. 

“Non-Statutory Option” shall mean an option not intended to satisfy the requirements of Code Section 422.

 “Optionee” shall mean the person to whom the Option is granted as specified in the Grant Notice.

 “Option Shares” shall mean the number of Ordinary Shares subject to the Option. 

“Option Term” shall have the meaning set forth in Section 2. 

“Ordinary Shares” shall mean the Company’s ordinary shares. 

  
 2 

 “Parent” shall mean any corporation (other than the Company) in an
unbroken chain of corporations ending with the Company, provided each corporation in the unbroken chain (other than the Company) owns, at the time of the determination, stock possessing fifty percent (50%) or more of the total combined voting
power of all classes of stock in one of the other corporations in such chain. 
 “Plan” shall mean the
Company’s Amended and Restated 2012 Share Option/Share Issuance Plan. 
 “Plan Administrator” shall
mean either the Board or a committee of the Board acting in its capacity as administrator of the Plan. 
 “Purchase
Agreement” shall mean the share purchase agreement in substantially the form of Exhibit C to the Grant Notice. 
 “Service” shall mean the Optionee’s performance of services for the Company (or any Parent or Subsidiary, whether now existing or subsequently established) in the capacity of
an Employee, a non-Employee member of the Board or a consultant or independent advisor. For purposes of this Agreement, Optionee shall be deemed to cease Service immediately upon the occurrence of either of the following events: (i) Optionee no
longer performs services in any of the foregoing capacities for the Company or any Parent or Subsidiary or (ii) the entity for which Optionee is performing such services ceases to remain a Parent or Subsidiary of the Company, even though the
Optionee may subsequently continue to perform services for that entity. Service shall not be deemed to cease during a period of military leave, sick leave, short or long term disability or other personal leave approved by the Company; provided,
however, that should such leave of absence exceed three (3) months, then for purposes of determining the period within which the Option may be exercised as such an Incentive Option under the U.S. federal tax laws, the Optionee’s Service
shall be deemed to cease on the first day immediately following the expiration of such three (3)-month period, unless Optionee is provided with the right to return to Service following such leave either by statute or by written contract. Except to
the extent otherwise required by law or expressly authorized by the Plan Administrator or by the Company’s written policy on leaves of absence, no Service credit shall be given for vesting purposes for any period the Optionee is on a leave of
absence. 
 “Subsidiary” shall mean any corporation (other than the Company) in an unbroken chain of
corporations beginning with the Company, provided each corporation (other than the last corporation) in the unbroken chain owns, at the time of the determination, shares possessing fifty percent (50%) or more of the total combined voting power
of all classes of shares in one of the other corporations in such chain. 

  
 3 

 EXHIBIT B 

AMENDED AND RESTATED 2012 SHARE OPTION/SHARE ISSUANCE PLAN 

  
 4 

 EXHIBIT C, 

SHARE PURCHASE AGREEMENT 
 IROKO PHARMACEUTICALS INC. 
 SHARE PURCHASE AGREEMENT 

This Share Purchase Agreement (this “Agreement”), is made this
             day of
                                         
                   , 20     by and between Iroko Pharmaceuticals Inc., a company incorporated under the laws of the British
Virgin Islands (the “Company”), and
                                         
                                Optionee under the Company’s Amended and Restated 2012
Share Option/Share Issuance Plan (the “Plan”). 
 All capitalized terms in this Agreement shall have the
meaning assigned to them in this Agreement or in the attached Appendix. 
 1. Exercise of Option 

(a) Exercise. Optionee hereby purchases
                     Ordinary Shares (the “Purchased Shares”) at the exercise price of
$                     per share (the “Exercise Price”) pursuant to the exercise of that certain option (the
“Option”) granted to Optionee pursuant to the Plan. 
 (b) Payment. Concurrently with the
delivery of this Agreement to the Company, Optionee Shall pay the aggregate Exercise Price for all of the Purchased Shares in cash or such other consideration allowable under the Plan and approved by the Plan Administrator and shall deliver whatever
additional documents may be required by the Option Agreement as a condition for exercise. 
 (c) Shareholder
Rights. Until such time as the Company exercises the First Refusal Right, Optionee (or any successor in interest) shall have all the rights of a shareholder (including voting, dividend and liquidation rights) with respect to the Purchased
Shares, subject, however, to the transfer restrictions imposed by this Agreement. 
 2. Securities Law Compliance 

(a) Investment Intent. Optionee is aware of the Company’s business affairs and financial condition and has acquired
sufficient information about the Company to reach an informed and knowledgeable decision to acquire the Purchased Shares. Optionee is acquiring the Purchased Shares for investment for Optionee’s own account only and not with a view to, or for
resale in connection with, any “distribution” thereof within the meaning of the 1933 Act. 

  
 5 

 (b) Restricted Securities. 

 

	 	(i)	The Purchased Shares have not been registered under the 1933 Act and are being issued to Optionee in reliance upon the exemption from such registration provided by
Section 4(2) of the 1933 Act or SEC Rule 504, 505, 506 or 701. Optionee acknowledges and understands that the Purchased Shares constitute “restricted securities” tinder the 1933 Act and have not been registered tinder the 1933 Act in
reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of Optionee’s investment intent as expressed herein. In this connection, Optionee understands that, in the view of the SEC, the
statutory basis for such exemption may be unavailable if Optionee’s representation was predicated solely upon a present intention to hold the Purchased Shares for the minimum capital gains period specified under tax statutes, for a deferred
sale, for or until an increase or decrease in the market price of the Purchased Shares, or for a period of one year or any other fixed period in the future. Optionee further understands chat the Purchased Shares must be held indefinitely unless they
are subsequently registered under the 1933 Act or an exemption from such registration is available. Optionee further acknowledges and understands that the Company is under no obligation to register the Purchased Shares. Optionee understands that the
certificate evidencing the Purchased Shares will be imprinted with the legends set forth herein and any other legend required under applicable state securities laws. 

 

	 	(ii)	Optionee is familiar with the provisions of Rule 701 and Rule 144, each promulgated under the 1933 Act, which, in substance, permit limited public resale of
“restricted securities” acquired, directly or indirectly from the issuer thereof, in a non-public offering subject to the satisfaction of certain conditions. Rule 701 provides that if the issuer qualifies under Rule 701 at the time of the
grant of the Option to the Optionee, the exercise will be exempt from registration tinder the 1933 Act. In the event the Company becomes subject to the reporting requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, ninety
(90) clays thereafter (or such longer period as any market stand-off agreement may require) the Purchased Shares exempt under Rule 701 may be resold, subject to the satisfaction of certain of the conditions specified by Rule 144, including
(1) the resale being made through a broker in an unsolicited “broker’s transaction” or in transactions directly with a market maker (as said term is defined under the 1934 Act); and, in the case of an affiliate, (2) the
availability of certain public information about the Company, (3) the amount of Purchased Shares, together with all other securities of the Company sold by Optionee that are required to be aggregated under Rule 144(e), being sold during any
three month period not exceeding the limitations specified in Rule 144(e), and (4) the timely tiling of a Form 144, if applicable. 

  
 6 

	 	(iii)	In the event that the Company does not qualify under Rule 701 at the time of grant of the Option, then the Purchased Shares may be resold in certain limited
circumstances subject to the provisions of Rule 144, which requires the resale to occur not less than one year after the later of the date the Purchased Shares were sold by the Company or the date the Purchased Shares were sold by an affiliate of
the Company, within the meaning of Rule 144; and, in the case of acquisition of the Purchased Shares by an affiliate, or by a non-affiliate who subsequently holds the Purchased Shares less than two years, the satisfaction of the conditions set forth
in sections (1), (2), (3) and (4) of the paragraph immediately above. 

 (c) Restrictions on
Disposition of Purchased Shares. 
  

	 	(i)	Optionee shall make no disposition of the Purchased Shares (other than a Permitted Transfer) unless and until there is compliance with all of the following
requirements: 

  

	 	A.	Optionee shall have provided the Company with a written summary of the terms and conditions of the proposed disposition. 

 

	 	B.	Optionee shall have provided the Company with written assurances, in form and substance satisfactory to the Company, that (A) the proposed disposition does not
require registration of the Purchased Shares under the 1933 Act or (B) all appropriate action necessary for compliance with the registration requirements of the 1933 Act or any exemption from registration available under the 1933 Act (including
Rule 144) has been taken. 

  

	 	(ii)	The Company shall not be required (i) to transfer on its books any Purchased Shares which have been sold or transferred in violation of the provisions of this
Agreement or (ii) to treat as the owner of the Purchased Shares, or otherwise to accord voting, dividend or liquidation rights to, any transferee to whom the Purchased Shares have been transferred in contravention of this Agreement.

 (d) Restrictive Legends. The share certificates representing the Purchased Shares shall be
endorsed with one or more of the following restrictive legends: 
 THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE’S SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL SUCH SHARES ARE REGISTERED UNDER SUCH LAWS OR AN OPINION OF
COUNSEL SATISFACTORY TO THE COMPANY IS OBTAINED TO THE EFFECT THAT SUCH REGISTRATION IS NOT REQUIRED. 
 THE SHARES REPRESENTED
BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN REPURCHASE RIGHTS AND RIGHTS OF FIRST REFUSAL GRANTED TO THE COMPANY AND 

  
 7 

 
ACCORDINGLY MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, ENCUMBERED, OR IN ANY MANNER DISPOSED OF EXCEPT IN CONFORMITY WITH THE TERMS OF A SHARE PURCHASE AGREEMENT BETWEEN THE COMPANY AND THE
REGISTERED HOLDER OF THE SHARES (OR THE PREDECESSOR IN INTEREST TO THE SHARES). A COPY OF SUCH AGREEMENT IS MAINTAINED AT THE COMPANY’S PRINCIPAL CORPORATE OFFICES. 
 3. Transfer Restrictions 
 (a) Restriction
on Transfer. Except for any Permitted Transfer, Optionee shall not transfer, assign, encumber or otherwise dispose of any Purchased Shares in contravention of the First Refusal Right, the Market Stand-Off or the transfer restrictions set
forth in Section 2. 
 (b) Transferee Obligations. Each person (other than the Company) to whom the
Purchased Shares are transferred by means of a Permitted Transfer must, as a condition precedent to the validity of such transfer, acknowledge in writing to the Company that such person is bound by the provisions of this Agreement and that the
transferred shares are subject to (a) the First Refusal Right, (b) the Market Stand-Off and (c) the transfer restrictions set forth in Section 2, to the same extent such shares would be so subject if retained by Optionee.

 (c) Market Stand-Off. 
  

	 	(i)	In connection with the Company’s IPO and any underwritten public offering by the Company of its equity securities on a securities exchange within two years after
the effective date of the Company’s IPO, Owner shall not sell, make any short sale of, hedge with, loan, hypothecate, pledge, grant any option for the purchase of, or otherwise dispose or transfer for value or otherwise agree to engage in any
of the foregoing transactions with respect to, any Purchased Shares without the prior written consent of the Company or its underwriters (the “Market Stand-Off’). The Market Stand-Off shall be in effect for such period of
time as may be requested by the Company or such underwriters; provided, however, that such period shall not exceed one hundred eighty (180) days, or if required by such underwriter, such longer period of time as is necessary to enable the
underwriter to issue a research report, analyst recommendation or opinion in accordance with the then-applicable rules and regulations of the Financial Regulatory Authority, Inc. and the applicable stock exchange, but in no event in excess of two
hundred ten (210) days following the effective date of the registration statement relating to such offering. 

  

	 	(ii)	Owner shall be subject to the Market Stand-Off provided card only if the officers and directors of the Company are also subject to similar restrictions.

  
 8 

	 	(iii)	Any new, substituted or additional securities which are by reason of any Recapitalization or Reorganization distributed with respect to the Purchased Shares shall be
immediately subject to the Market Stand-Off. 

  

	 	(iv)	In order to enforce the Market Stand-Off, the Company may impose stop-transfer instructions with respect to the Purchased Shares until the end of the applicable
stand-off period. 

 4. Right of First Refusal 

(a) Grant. The Company is hereby granted the right of first refusal (the “First Refusal Right”)
exercisable in connection with any proposed transfer of the Purchased Shares. For purposes of this Section 4, the term “transfer” shall include any sale, assignment, pledge, encumbrance or other disposition of the Purchased
Shares intended to be made by Owner, but shall not include any Permitted Transfer. 
 (b) Notice of Intended
Disposition. In the event any Owner of the Purchased Shares desires to accept a bona fide third-party offer for the transfer of any or all of such shares (the Purchased Shares subject to such offer to be hereinafter referred to as the
“Target Shares”), Owner shall promptly (a) deliver to the Company written notice (the “Disposition Notice”) of the terms of the offer, including the purchase price and the identity of the
third-party offeror, and (b) provide satisfactory proof that the disposition of the Target Shares to such third-party offeror would not be in contravention of the provisions set forth in Sections 2 and 3. 

(c) Exercise of the First Refusal Right. The Company shall have the right to repurchase any or all of the Target Shares
subject to the Disposition Notice upon the same terms as those specified therein or upon such other terms (not materially different from those specified in the Disposition Notice) to which Owner consents. Such right shall be exercisable by delivery
of written notice (the “Exercise Notice”) to Owner prior to the twenty-fifth day following receipt of the Disposition Notice. If such right is exercised with respect to all the Target Shares, then the Company shall effect the
repurchase of such shares, including payment of the purchase price, not more than five business days after delivery of the Exercise Notice; and at such time the certificates representing the Target Shares shall be delivered to the Company.

 Should the purchase price specified in the Disposition Notice be payable in property other than cash or evidences of
indebtedness, the Company shall have the right to pay the purchase price in the form of cash equal in amount to the value of such property. If Owner and the Company cannot agree on such cash value within ten days after the Company’s receipt of
the Disposition Notice, the valuation shall be made by an appraiser of recognized standing selected by Owner and the Company or, if they cannot agree on an appraiser within twenty days after the Company’s receipt of the Disposition Notice, each
shall select an appraiser of recognized standing and the two appraisers shall designate a third appraiser of recognized standing, whose appraisal shall be determinative of such value. The cost of such appraisal shall be shared equally by Owner and
the Company. The closing shall then be held on the later of (i) the fifth business day following delivery of the Exercise Notice or (ii) the fifth business day after such valuation shall have been made. 

  
 9 

 (d) Non-Exercise of the First Refusal Right. In the event the Exercise Notice
is not given to Owner prior to the expiration of the twenty-five clay exercise period. Owner shall have a period of thirty days thereafter in which to sell or otherwise dispose of the Target Shares to the third-party offeror identified in the
Disposition Notice upon terms (including the purchase price) no more favorable to such third-party offeror than those specified in the Disposition Notice; provided, however, that any such sale or disposition must not be effected in contravention of
the provisions of Sections 2 and 3. The third-party offeror shall acquire the Target Shares subject to the First Refusal Right and the provisions and restrictions of Section 2 and Paragraph 3(c), and any subsequent
disposition of the acquired shares must be effected in compliance with the terms and conditions of such First Refusal Right and the provisions and restrictions of Section 2 and Paragraph 3(c). In the event Owner does not effect
such sale or disposition of the Target Shares within the specified thirty day period, the First Refusal Right shall continue to be applicable to any subsequent disposition of the Target Shares by Owner until such right lapses. 

(e) Partial Exercise of the First Refusal Right. In the event the Company makes a timely exercise of the First Refusal
Right with respect to a portion, but not all, of the Target Shares specified in the Disposition Notice, Owner shall have the option, exercisable by written notice to the Company delivered within five business days after Owner’s receipt of the
Exercise Notice, to effect the sale of the Target Shares pursuant to either of the following alternatives: 
  

	 	(i)	sale or other disposition of some or all the Target Shares to the third-party offeror identified in the Disposition Notice, but in full compliance with the requirements
of Paragraph (d), as if the Company did not exercise the First Refusal Right; or 

  

	 	(ii)	sale to the Company of the portion of the Target Shares which the Company has elected to purchase, such sale to be effected in substantial conformity with the
provisions of Paragraph 4(c). The First Refusal Right shall continue to be applicable to any subsequent disposition of the remaining Target Shares until such right lapses. 

Owner’s failure to deliver timely notification to the Company shall be deemed to be an election by Owner to sell the Target Shares
pursuant to alternative (i) above. 
 (f) Recapitalization/Reorganization. 

 

	 	(i)	Any new, substituted or additional securities or other property which is by reason of any Recapitalization distributed with respect to the Purchased Shares shall be
immediately subject to the First Refusal Right. 

  

	 	(ii)	In the event of a Reorganization, the First Refusal Right shall remain in full force and effect and shall apply to the new capital shares or other property received in
exchange for the Purchased Shares in consummation of the Reorganization. 

 (g) Lapse. The First
Refusal Right shall lapse upon the earlier to occur of (a) an IPO or (b) the acquisition of the Company by an entity that is traded on a stock exchange. However, the Market Stand-Off shall continue to remain in full force and effect
following the lapse of the First Refusal Right, in the case of a transaction described in (a) above. 

  
 10 

 5. General Provisions 
 (a) Assignment. The Company may assign the First Refusal Right to any person or entity selected by the Plan Administrator, including (without limitation) one or more shareholders of the
Company. 
 (b) At Will Employment. Nothing in this Agreement or in the Plan shall confer upon Optionee any right
to continue in Service for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Company (or any Parent or Subsidiary employing or retaining Optionee) or of Optionee, which rights are hereby expressly
reserved by each, to terminate Optionee’s Service at any time for any reason, with or without cause, subject to the terms of any employment agreement and applicable law. 
 (c) Notices. Any notice required to be given under this Agreement shall be in writing and shall be deemed effective Upon personal delivery or on the third day following deposit in the U.S.
mail or other international mail delivery source, registered or certified, postage prepaid and properly addressed to the party entitled to such notice at the address indicated below such party’s signature line on this Agreement or at such other
address as such party may designate by ten days advance written notice under this paragraph to all other parties to this Agreement. 
 To the extent allowed by applicable law, Optionee generally consents to the delivery of any notice by electronic transmission (“Electronic Notice”) at the electronic mail address
or the facsimile number as set forth in the books of the Company. To the extent that any notice given via electronic transmission is returned or undeliverable for any reason, the foregoing consent shall be deemed to have been revoked until a new or
corrected electronic mail address has been provided, and such attempted Electronic Notice shall be ineffective and deemed to not have been given. Optionee agrees to promptly notify the Company of any change in Optionee’s electronic mail
address, but failure to do so shall not affect the foregoing. 
 (d) No Waiver. The failure of the Company in any
instance to exercise the First Refusal Right shall not constitute a waiver of any other repurchase rights and/or rights of first refusal that may subsequently arise under the provisions of this Agreement or any other agreement between the Company
and Optionee. No waiver of any breach or condition of this Agreement shall be deemed to be a waiver of any other or subsequent breach or condition, whether of like or different nature. 

(e) Cancellation of Shares. If the Company shall make available, at the time and place and in the amount and form provided
in this Agreement, the consideration for the Purchased Shares to be repurchased in accordance with the provisions of this Agreement, then from and after such time, the person from whom such shares are to be repurchased shall no longer have any
rights as a holder of such shares (other than the right to receive payment of such consideration in accordance with this Agreement). Such shares shall be deemed purchased in accordance with the applicable provisions hereof, and the Company shall be
deemed the owner and holder of such shares, whether or not the certificates therefor have been delivered as required by this Agreement. 

  
 11 

 (f) Optionee Undertaking. Optionee hereby agrees to take whatever additional
action and execute whatever additional documents the Company may deem necessary or advisable in order to carry out or effect one or more of the obligations or restrictions imposed on either Optionee or the Purchased Shares pursuant to the provisions
of this Agreement. 
 (g) Construction. The Plan is incorporated herein by reference. In the event of a conflict
between the terms of the Plan and the terms of this Agreement, the terms of this Agreement shall prevail. All decisions of the Plan Administrator with respect to any question or issue arising under the Plan or this Agreement shall be conclusive and
binding on all persons having an interest in this option. 
 (h) Governing Law. The interpretation, performance
and enforcement of this Agreement shall be governed by the laws of the State of Delaware without giving effect to that State’s choice of law or conflict-of-laws rules. 
 (i) Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument.

 (j) Successors and Assigns. The provisions of this Agreement shall inure to the benefit of, and be binding
upon, the Company and its successors and assigns and upon Optionee, Optionee’s permitted assigns and the legal representatives, heirs and legatees of Optionee’s estate, whether or not any such person shall have become a party to this
Agreement and have agreed in writing to join herein and be bound by the terms hereof. 
 IN WITNESS WHEREOF, the parties have
executed this Share Purchase Agreement on the day and year first indicated above. 
  

			
	IROKO PHARMACEUTICALS INC.
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 

  

			
	OPTIONEE
		
	Signature:	 	 
		
	Printed Name:	 	 
		
	Address:	 	 
		
		 	 
		
	SSN:	 	 

  
 12 

 APPENDIX 

The following definitions shall be in effect tinder the Agreement: 

A. “Agreement” shall mean this Share Purchase Agreement. 

B. “Board” shall mean the Company’s Board of Directors. 

C. “Code” shall mean the Internal Revenue Code of 1986, as amended. 

D. “Company” shall mean Iroko Pharmaceuticals Inc., a company incorporated under the laws of the British Virgin
Islands or any successor corporation to all or substantially all of the assets or voting shares of Iroko Pharmaceuticals Inc. which shall by appropriate action adopt the Plan. 
 E. “Disposition Notice” shall have the meaning assigned to .Such term in Paragraph 4(b). 
 F. “Exercise Price” shall have the meaning assigned to such term in Paragraph 1(a). 
 G. “First Refusal Right” shall mean the right granted to the Company in accordance with Section 4. 

H. “Grant Notice” shall mean the Notice of Grant of Share Option pursuant to which Optionee has been informed of
the basic terms of the Option. 
 I. “Incentive Option” shall mean an option which satisfies the
requirements of Code Section 422. 
 J. “IPO” shall mean the first public offering of the Class C
Shares, or any shares issued to Optionee upon a Reorganization, on any stock exchange. 
 K. “Market
Stand-Off” shall mean the market stand-off restriction specified in Paragraph 3(c). 
 L. “1933
Act” shall mean the Securities Act of 1933, as amended. 
 M. “1934 Act” shall mean the
Securities Exchange Act of 1934, as amended. 
 N. “Option” shall have the meaning assigned to -such
term in Paragraph 1(a). 
 O. “Option Agreement” shall mean all agreements and other documents
evidencing the Option. 
 P. “Option Shares” shall mean the Ordinary Shares subject to the option.

 Q. “Optionee” shall mean the person to whom the Option is granted tinder the Plan. 

R. “Ordinary Shares” shall mean the Company’s ordinary shares. 

 S. “Owner” shall mean Optionee and all subsequent holders of the
Purchased Shares who derive their chain of ownership through a Permitted Transfer from Optionee. 
 T.
“Parent” shall mean any corporation (other than the Company) in an unbroken chain of corporations ending with the Company, provided each corporation in the unbroken chain (other than the Company) owns, at the time of the
determination, shares possessing 50% or snore of the total combined voting power of all classes of shares in one of the other corporations in such chain. 
 U. “Permitted Transfer” shall mean (i) a gratuitous transfer of the Purchased Shares, provided and only if Optionee obtains the Company’s prior written consent to such
transfer, (ii) a transfer of title to the Purchased Shares effected pursuant to Optionee’s will or the laws of inheritance following Optionee’s death or (iii) a transfer to the Company in pledge as security for any purchase-money
indebtedness incurred by Optionee in connection with the acquisition of the Purchased Shares. 
 V.
“Plan” shall mean the Company’s Amended and Restated 2012 Share Option/Share Issuance Plan. 
 W.
“Plan Administrator” shall mean either the Board or a committee of the Board acting in its capacity as administrator of the Plan. 
 X. “Purchased Shares” shall have the meaning assigned to such term in Paragraph l(a). 
 Y. “Recapitalization” shall mean any share split, share dividend, recapitalization, combination of shares, exchange of shares or other change affecting the Company’s
outstanding Ordinary Shares as a class without the Company’s receipt of consideration. 
 Z.
“Reorganization” shall mean any of the following transactions: 
  

	 	1.	a merger or consolidation in which the Company is not the surviving entity; 

 

	 	2.	a sale, transfer or other disposition of all or substantially all of the Company’s assets; 

 

	 	3.	a reverse merger in which the Company is the surviving entity but in which the Company’s outstanding voting securities are transferred in whole or in part to a
person or persons different from the persons holding those securities immediately prior to the merger; or 

  

	 	4.	any transaction effected primarily to change the state in which the Company is incorporated or to create a holding company structure. 

AA. “SEC” shall mean the Securities and Exchange Commission. 

 BB. “Service” shall mean the Optionee’s performance of services
for the Company (or any Parent or Subsidiary, whether now existing or subsequently established) in the capacity of an Employee, a non-Employee member of the board of directors or a consultant or independent advisor. For purposes of this Agreement,
Optionee shall be deemed to cease Service immediately upon the occurrence of the either of the following events: (i) Optionee no longer performs services in any of the foregoing capacities for the Company or any Parent or Subsidiary or
(ii) the entity for which Optionee is performing such services ceases to remain a Parent or Subsidiary of the Company, even though the Optionee may subsequently continue to perform services for that entity. Service shall not be deemed to cease
during a period of military leave, sick leave or other personal leave approved by the Company; provided, however, that should such leave of absence exceed three (3) months, then for purposes of determining the period within which the Option (if
designated as an incentive Option in the Grant Notice) may be exercised as such an Incentive Option under the federal tax laws, the Optionee’s Service shall be deemed to cease on the first day immediately following the expiration of such three
(3)-month period, unless Optionee is provided with the right to return to Service following such leave either by statute or by written contract. 
 CC. “Subsidiary” shall mean any corporation (other than the Company) in an unbroken chain of corporations beginning with the Company, provided each corporation (other than the last
corporation) in the unbroken chain owns, at the time of the determination, shares possessing 50% or more of the total combined voting power of all classes of shares in one of the other corporations in such chain. 

DD. “Target Shares” shall have the meaning assigned to such term in paragraph 4(b).EX-10.13

 Exhibit 10.13 
 [***] indicates material that has been omitted pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission. A complete copy of this agreement, including redacted
portions so indicated, has been filed separately with the Securities and Exchange Commission. 
 CONFIDENTIAL SERVICE AGREEMENT

 This agreement (the “Agreement”) is made as of November 30, 2012 (the “Effective Date”) by and
between VENTIV COMMERCIAL SERVICES, LLC, a New Jersey limited liability company (“Ventiv”) and IROKO PHARMACEUTICALS LLC, a Delaware limited liability company (“Iroko”). Ventiv and Iroko may each be referred to herein as a
“Party” and collectively as the “Parties”. 
 1. Background. Ventiv and its Affiliates as defined below,
(collectively “Ventiv”) provide pharmaceutical companies with a range of services designed to help such companies achieve full commercialization of their products, including contracted sales force services. Iroko desires for Ventiv to
provide such services to Iroko, all under the terms and conditions set forth in this Agreement, as well as in each separate project agreement, statement of work, work order or equivalent document (the “SOW”), for each project the Parties
wish to be governed by the terms and conditions of this Agreement, to be executed by the Parties. 
 The Parties desire for the
terms and conditions set forth in this Agreement to govern the relationship between the Parties. Unless otherwise specifically set forth in an SOW, in the event of a conflict or inconsistency between the terms and conditions set forth in this
Agreement and the terms and conditions set forth in an SOW, the terms and conditions set forth in this Agreement shall take precedence, govern and control. 
 The Parties hereby acknowledge that the terms set forth in this Agreement shall be incorporated by reference into each SOW, as if fully set forth at length therein. 

2. Definitions. In addition to the other terms defined elsewhere herein, the terms set forth below shall have the meanings set forth below when
used in this Agreement. 
 2.1 “Affiliates” means with respect to any entity, any other entity directly or
indirectly, through one or more intermediaries, controlling, controlled by or under common control with such entity. As used in this definition, the term “control” (including “controlled by” or “under common control
with”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of an entity, whether through ownership of voting securities, as trustee, by contract or otherwise. 

2.2 “Applicable Law” means all federal, state and local laws, and the rules, regulations, guidances, guidelines and
requirements of all governmental and regulatory authorities in effect from time to time applicable to the manufacture, marketing, promotion, distribution and sale of the Product in the Territory, including without limitation the Federal Food, Drug,
and Cosmetic Act, as it may be amended (“FDCA”), the Prescription Drug Marketing Act of 1987 (“PDMA”) and “fraud and abuse”, antikickback, consumer protection and false claims statutes and regulations, as well as
applicable PhRMA and other industry codes. 

 2.3 “Call” means the activity undertaken by Ventiv Sales Representatives to
deliver a sales presentation to a Target and includes providing the Target with Product samples and Product Literature. 
 2.4
“Call Plan” means a plan jointly designed by Iroko and Ventiv and to be finally approved by Iroko, which is intended to enhance the efficiency and effectiveness of Ventiv Sales Representatives in making Calls. The Call Plan will be
maintained by Ventiv at its offices with a copy of such Call Plan maintained by Iroko at its offices, and may be amended or reconfigured from time to time solely at Iroko’s written request. 

2.5 “Competing Product” means any drug, medical device or combination thereof, whether prescription or over-the-counter,
now or in the future, with the same or similar mechanism of action as any Iroko Product or that is indicated for or is used to diagnose, prevent, treat or cure the same disease or condition for which any Iroko Product is indicated or used.

 2.6 “Deployment Date” means the Ventiv Sales Representatives’ first day in the field with customers
after the successful completion of initial training. 
 2.7 “Health Care Professional” means any professional
person working within a medical office setting who in the course of his or her professional activities may prescribe, dispense, recommend, purchase, supply or administer prescription product. 

2.8 “Iroko Product” or “Product” means the Iroko drugs ZORVOLEXTM, TIFORBEXTM and such other drugs
designated by Iroko and mutually agreed on by the Parties. 
 2.9 “PDUFA Date” means the date on which the US
Food and Drug Administration (“FDA”) provides as the date on which the FDA will make a determination whether the Iroko Product may be marketed in the United States, such date to be communicated by Iroko to Ventiv as soon as such date is
provided by the FDA. 
 2.10 “Plan of Action (POA)” means a document that refers to the specific steps that need
to be taken or activities that need to be performed well in order for Iroko’s commercial strategy to succeed. The POA provides clarity around what selling activities will be done and by whom, the time horizon for completion and the types of
resources that will be available to support those activities. 
 2.11 “Product Literature” means promotional,
educational and other information concerning the Iroko Product either in a written or electronic format provided to Ventiv by Iroko. All Product Literature shall be approved by Iroko. The Ventiv Sales Representatives shall utilize the Product
literature only for the uses for which they have been approved by Iroko. Product Literature approved for promotional use shall be utilized by Ventiv Sales Representatives when making Calls. 

  
 2 

 2.12 “Project Items” means Promotional Materials, demonstration materials
and samples which Iroko supplies to Ventiv in connection with the performance of Services by Ventiv under this Agreement. 
 2.13
“Project Team” means, collectively, Ventiv employees who serve in the role of the National Business Director, Training Manager, Project Manager or Employee Relations Managers, in providing Services under this Agreement. 

2.14 “Promotional Materials” means all promotional support items approved by Iroko for use in marketing, promoting, and
selling of Iroko Product, including without limitation the Product labeling and package inserts, sales aids and selling materials 
 2.15 “Recruitment Start Date” means the date 60 days prior to the PDUFA Date. 
 2.16 “Regional Business Manager (RBM)” means any individual employed by Iroko who is responsible for leading, monitoring and supporting the regional achievement of sales objectives and
the implementation of both the POA and marketing plan for each product within the region. 
 2.17 “Sales
Presentation” means a face-to-face contact in a medical office setting by a Ventiv Sales Representative with a Target and involves a presentation highlighting the product features and benefits for its approved indications, as well as risks
and product safety information. 
 2.18 “Sales Representative Start Date” means the date which is [***] [***]
after Iroko receives FDA approval for either ZORVOLEXTM or TIFORBEXTM, on or about which date Sales Representatives will be on Ventiv payroll to provide the Services hereunder. 

2.19 “Sales Representative Territory” means the local zip code based geography in which a Sales Representative works on a
daily basis for Ventiv. 
 2.20 “Second Line Leader” means any individual employed by Iroko, including, but not
limited to an Iroko Area Sales Vice President, who is responsible for leading, coaching, managing and supporting Iroko’s RBMs on a daily basis in the achievement of sales objectives and the implementation of the Iroko marketing plan and POA.

 2.21 “Target” means a Health Care Professional identified by Iroko as a potential prescription writer and/or
customer for Iroko Product 
 2.22 “Territory” means the United States of America, including its territories,
possessions and Puerto Rico in which Iroko Product will be promoted. 
 2.23 “Trademarks” means any trademarks,
service marks, trade names and trade dress used, owned or licensed by Iroko or its Affiliates. 

  
 *** Portions of this page
have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission. 

  
 3 

 3. The Services. Ventiv will provide Iroko with a field force that consists of up to three hundred
and fifty (350) full-time sales representatives (collectively, “Ventiv Sales Representatives”) who shall exclusively promote and sell Iroko Product and distribute Iroko Product Samples and Product Literature to Targets. Iroko may increase
the number of Sales Representatives by providing Ventiv with a completed “Additional Sales Representative(s) Request Form” the form of which is attached hereto as Exhibit D. The services provided by Ventiv as more fully set forth in the
attached Exhibit A shall include recruiting and training of the Ventiv Sales Representatives, implementation of the Call Plan, deployment of the Ventiv Sales Representatives, and execution of a sampling program (collectively, the
“Services”). Sampling of the Product by Ventiv Sales Representatives shall be conducted in accordance with Exhibit C attached hereto. 

4. Right to Sell Iroko Product. Iroko Product shall be promoted by Ventiv under trademarks owned by or licensed to Iroko and is a product which is
either owned by Iroko and/or which Iroko has all lawful authority necessary to market and sell as Iroko Product. This Agreement does not constitute a grant to Ventiv of any property right or interest in Iroko Product or the trademarks owned by or
licensed to Iroko and/or any other intellectual property rights which Iroko owns now or in the future. Ventiv recognizes the validity of and the title to all of Iroko’s owned or licensed trademarks, trade names and trade dress in any country in
connection with Iroko Product, whether registered or not. 
 5. Iroko Responsibilities. Iroko shall be responsible for: 

5.1 identifying Targets for Iroko Product; 
 5.2 establishing and maintaining the Call Plan for use by the Ventiv Sales Representatives in presenting Iroko Product; 
 5.3 producing and delivering Iroko Product samples and Iroko Product Literature to Ventiv in accordance with Applicable Law, including but not limited to PDMA; 

5.4 reviewing and approving all Product Promotional Materials and Product Literature and for ensuring all such materials comply with
Applicable Law; 
 5.5 hiring Regional Business Managers and Second Line Leaders, all of whom shall be Iroko employees and Iroko
shall be responsible for salary, bonus, benefits and all employment matters with respect to such Iroko employees; 
 5.6
informing Ventiv promptly of any changes which Iroko believes are necessary or appropriate in the Product Literature or in information concerning Iroko Product in order to be in compliance with Applicable Law; 

5.7 obtaining third party data; 

  
 4 

 5.8 responding timely to any inquiry concerning Iroko Product from any Health Care
Professional; and 
 5.9 notifying Ventiv in the event it becomes subject to a federally mandated Corporate Integrity Agreement
(CIA) that requires Ventiv to provide Iroko with data, training, analysis, oversight or certifications that are not contemplated by the Services described herein. In such event, the Parties shall mutually agree on an appropriate allocation of costs
and expenses associated with Ventiv’s provision of such CIA related data, training, analysis, oversight or certifications not included in the scope of Services provided under this Agreement or any related SOW. 

6. Ventiv Responsibilities. Ventiv shall be responsible for: 
 6.1 validating Targets for Iroko Product and ensuring that Ventiv Sales Representatives are presenting Iroko Product by making Calls pursuant to the Call Plan on Targets; 

6.2 using only Promotional Materials and Product Literature approved and provided by Iroko and ensuring that personnel performing the
Services do not develop, create or use any other materials or literature in connection with the marketing, sales or promotion of Iroko Product; 
 6.3 ceasing immediately the use of any Promotional Materials and Product Literature when Ventiv is instructed to do so by Iroko; 
 6.4 ensuring that Ventiv Sales Representatives performing the Services do not change Promotional Materials including, without limitation, by underlining or otherwise highlighting any text or graphics or
adding any notes thereto; 
 6.5 limiting their statements and claims regarding Iroko Product, including as to efficacy and
safety, to those which are consistent with the Product labels, package inserts and Promotional Materials; 
 6.6 ensuring that
Ventiv personnel do not make any false or misleading statements about Iroko Product or any Competing Product; 
 6.7 reporting
all field activities and expenditures in a manner that is timely, accurate and honest, and in accordance with policies and procedures for the applicable reporting systems; and 
 6.8 cooperating with Iroko, at Iroko’s expense, to conduct any necessary recalls of Iroko Product, Promotional Materials and/or Product Literature. 

  
 5 

 7. Ventiv Personnel. 
 7.1 Qualifications. Ventiv shall ensure that each individual who provides Services is an employee of Ventiv, and has and continues to maintain, throughout the term of this Agreement, all applicable
professional licenses and certifications required by Applicable Law and by the professional boards and bodies having authority over them with respect to the provision of Services by such individual hereunder. The Services shall be performed by
individuals whom Ventiv has determined are qualified to perform such services and in accordance with Section 9 and Exhibit A attached hereto. 
 7.2 Management. Subject to the other provisions of this Agreement, Ventiv shall have sole discretion over and responsibility for the hiring, training, terms and conditions of employment,
supervision, performance evaluation and discipline, management, oversight, and termination of its personnel providing Services, but will reasonably consult with Iroko to ensure to Iroko’s satisfaction that the Services are being performed.

 7.3 Identification of Personnel. Ventiv shall provide Iroko with a list of all individuals who will provide Services
and provide periodic updates of the list as reasonably requested by Iroko. An e-mail address and phone number for each individual must be provided. 
 7.4 Disciplining and Removal of Personnel. Ventiv has sole authority to counsel, discipline, remove and replace individuals providing Services under this Agreement; provided, however, that Iroko
may request that Ventiv remove any of Ventiv’s personnel providing Services upon written notification setting forth Iroko’s reasons for requesting the removal including identifying the individual’s actions and/or behavior that support
the request; such request by Iroko will not be unreasonably denied. Ventiv shall promptly investigate any reports made by Iroko of problematic behavior by individuals providing Services and will apply such counseling or discipline as may be
warranted in accordance with Ventiv’s human resources policies and considering Iroko’s prior request for removal. All employment decisions regarding a Ventiv employee shall be made solely and exclusively by Ventiv and are subject to
compliance at all times with Ventiv’s human resource policies and procedures. In the event Ventiv removes any personnel who are providing Services or adds any personnel for the purpose of providing Services, Ventiv shall notify Iroko within
forty-eight (48) hours following such action. Notwithstanding the foregoing, Ventiv shall not remove any individual identified as a project leader without providing Iroko (i) prior reasonable notification of its intent to do so and
including where possible the reasons for such removal, and (ii) a reasonable opportunity to express its views on the matter. Any action or omission of Ventiv’s personnel shall be deemed to constitute an action or omission on the part of
Ventiv. 

  
 6 

 8. Ventiv Compensation. 
 8.1 Fees. In full and complete compensation for all Services provided by Ventiv and for all obligations assumed by Ventiv hereunder, Iroko agrees to pay to Ventiv the fees, expenses and other
amounts set forth and in accordance with Exhibit B attached hereto. 
 8.2 Expenses. Iroko shall reimburse Ventiv at
actual cost for reasonable out-of-pocket expenses incurred in performing services under this Agreement following receipt of documentation for expenditures in accordance with Iroko’s business and entertainment policies and procedures. All
out-of-pocket expenses, including without limitation, travel expenses, shall be paid by Iroko at cost without mark-up. 
 8.3
[***] 
 8.4 Taxes. All amounts payable by Iroko shall be inclusive of all local, municipal, state, and federal sales and
use taxes, excise taxes, taxes on personal property owned by Ventiv, duties, and all other governmental fees and taxes or charges applicable to the performance of the Services. 
 8.5 No Additional Compensation. Except for the compensation set forth herein, Ventiv acknowledges and agrees that it is entitled to receive no other amounts from Iroko or any other party.

 8.6 Invoices and Payment. Ventiv shall issue invoices to Iroko for payment and reimbursement of fees and expenses
except as otherwise stated in the attached Exhibit B. Ventiv shall submit a statement setting forth the services performed, number and days worked by Ventiv’s personnel, and expenses incurred during the period covered. Iroko will pay undisputed
invoiced amounts within thirty (30) days following receipt of the invoice. 
 9. Compliance with Law. This Agreement is subject to,
and the Parties will comply with, Applicable Law, and neither party will be required to perform any act or to refrain from any act that would violate Applicable Law. Additionally, during the term of the Agreement, Ventiv shall: 

9.1 not assign any individual to provide Services who is currently excluded, debarred, suspended, or otherwise ineligible to participate
in federal healthcare or other programs, including any individuals listed on relevant websites of the Office of Inspector General or the General Services Administration (e.g., http://oig.hhs.gov/fraud/exclusions.html and
http://epls.arnet.gov/); 

  
 *** Portions of this page
have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission. 

  
 7 

 9.2 notify Iroko immediately if any individual assigned to provide Services becomes
excluded, debarred, suspended or otherwise ineligible to participate in any Federal programs and immediately terminate any such individual’s provision of Services to Iroko; 

9.3 require all individuals assigned to provide Services to sign an acknowledgment, in a form to be provided by Iroko and reasonably
agreed by Ventiv, that they will abide by Iroko’s Code of Conduct in connection with the work performed for Iroko; 
 9.4
require all individuals assigned to provide Services to complete within thirty (30) days certain Iroko annual training requirements, including without limitation training delivered through Iroko’s training system or any other program used
by Iroko; and 
 9.5 cooperate with Iroko and its representatives to the extent reasonably necessary for Iroko to comply with
obligations Iroko may have under Applicable Law, including any judicial activities or other proceedings and investigations. 

9.6 notify Iroko within one (1) business day after it becomes aware of any potential or actual violation of applicable federal
healthcare law (e.g. FDCA, PDMA, “fraud and abuse”, antikickback, consumer protection and false claims statutes and regulations, as well as applicable PhRMA, state, or other industry codes), disclose to Iroko all facts and circumstances
known to Iroko at that time regarding the potential or actual violation, and cooperate fully with Iroko in connection with my investigation and/or resolution. 
 10. Confidentiality; Ownership of Property. 
 10.1 Confidential
Information. During the performance of the Services contemplated by this Agreement, each Party may learn confidential, proprietary, and/or trade secret information of the other Party (“Confidential Information”). The Party disclosing
Confidential Information shall be referred to as the “Disclosing Party” and the Party receiving Confidential Information shall be referred to as the “Receiving Party.” 

10.2 Definition. Confidential Information means any information, unknown to the general public, which is disclosed by the
Disclosing Party to the Receiving Party under this Agreement. Confidential Information includes, without limitation, technical, trade secret, commercial and financial information about either Party’s (a) research or development;
(b) marketing plans or techniques, contacts or customers; (c) organization or operations; (d) business development plans (e.g., licensing, supply, acquisitions, divestitures or combined marketing); (e) products, licenses,
trademarks, patents, other types of intellectual property or any other contractual rights or interests (including without limitation processes, procedures and business practices involving trade secrets or special know-how) and (f) in the case
of Ventiv, the names, addresses, phone numbers and work assignments of Ventiv employees. The Receiving Party shall neither use or disclose Confidential Information from the Disclosing Party for any purpose other than is specifically allowed by this
Agreement. 

  
 8 

 10.3 Duties on Agreement Expiration/Termination. Upon the expiration or termination
of this Agreement, the Receiving Party shall return to the Disclosing Party all tangible forms of Confidential Information, including any and all copies and/or derivatives of Confidential Information made by either Party or their employees as well
as any writings, drawings, specifications, manuals or other printed or electronically stored material based on or derived from, Confidential Information. Any material or media not subject to return must be destroyed. With respect to data relating to
Services provided under this Agreement and which are electronically stored on Ventiv systems, Ventiv shall return such data to Iroko upon termination or expiration of this Agreement and shall certify to Iroko that all copies have been returned and
deleted from Ventiv systems. The Receiving Party shall not disclose to third parties any Confidential Information or any reports, recommendations, conclusions or other results of work under this Agreement without prior written consent of an officer
of the Disclosing Party. The obligations set forth in this Section 10, including the obligations of confidentiality and non-use shall be continuing and shall survive the expiration or termination of this Agreement and will continue for a period
of three (3) years. 
 10.4 Exempt Information; Required Disclosure. The obligations of confidentiality and non-use
set forth herein shall not apply to the following: (i) Confidential Information at or after such time that it is or becomes publicly available through no fault of the Receiving Party; (ii) Confidential Information that is already
independently known to the Receiving Party as shown by prior written records; (iii) Confidential Information at or after such time that it is disclosed to the Receiving Party by a third party with the legal right to do so;
(iv) Confidential Information required to be disclosed pursuant to judicial process, court order or administrative request, provided that the Receiving Party shall so notify the Disclosing Party sufficiently prior to disclosing such
Confidential Information as to permit the Disclosing Party to seek a protective order and provide assistance in obtaining such an order to prevent disclosure. 
 10.5 Property Ownership. All materials and documents supplied to either Party during the Term of this Agreement, including but not limited to marketing material, sales force automation software,
report designs, and sales training materials shall be the sole and exclusive property of the originator of those materials and developments. Each Party agrees to hold all such property and developments, confidential in accordance with this
Section 10 of the Agreement. 
 10.6 Agreement Confidential. The existence, subject matter and terms of this
Agreement shall be deemed Iroko’s Confidential Information. 
 10.7 No Use of Names. Neither party shall use the name
of the other party or its Affiliates without the other party’s prior written consent. 
 10.8 Injunctive Relief. Any
breach of the provisions of this Section 10 may result in significant and irreparable damages to the discloser. Accordingly, the discloser will be entitled, in addition to any other remedies available at law, to seek injunctive or other
equitable relief by a court of appropriate jurisdiction in the event of any breach or threatened breach hereof. 

  
 9 

 11. Independent Contractors. Ventiv and its directors, officers, employees and all members of
the Project Team are at all times independent contractors with respect to Iroko. No member of the Project Team shall be deemed to be an employee of Iroko. Ventiv is solely responsible for withholding federal, state, or local income tax or other
payroll tax of any kind on behalf of its employees. Ventiv employees are not eligible for, are not entitled to, and shall not participate in any of Iroko’s benefit plans or programs, including but not limited to, any pension plan, welfare plan,
profit sharing plan or any other “employee pension benefit plan”, or insurance plan or any other “employee welfare benefit plan” or “employee benefit plan” (as those terms are defined by the Employee Retirement Income
Security Act of 1974, as amended) or any other plan, program, fringe, award, bonus, perquisite or other benefit (such as, but not limited to, vacation and holiday pay) incident to employment offered from time to time by Iroko. Ventiv is responsible
for the payment of all required payroll taxes, whether federal, state, or local in nature, including, but not limited to income taxes, Social Security taxes, Federal Unemployment Compensation taxes, and any other fees, charges, licenses, or similar
payments required by law. 
 12. Iroko Conversion Option (Open Opportunity Hiring and Block Selection). 

12.1 Notwithstanding Section 15, below, during the Term (or any Additional Term) and after the Deployment Date, Iroko may consider,
solicit, employ or retain one or more Ventiv Sales Representatives performing Services hereunder (an “Open Opportunity Hiring”) along with other qualified candidates for open and advertised sales representative positions. Iroko shall give
sixty (60) days prior written notice to Ventiv of any Open Opportunity Hiring. Should there be Open Opportunity Hiring by Iroko and a Ventiv employee is selected for the position, Ventiv will backfill the respective position so as to maintain
the previously agreed upon number of Ventiv Sales Representatives performing Services hereunder. In the event Iroko wishes to implement an Open Opportunity Hiring during the Term (or any Additional Term), Iroko shall pay Ventiv [***] for each
replacement/backfill Ventiv Sales Representative. 
 12.2 Notwithstanding Section 15, below, Iroko may consider, solicit,
employ or retain one or more Ventiv Sales Representatives performing Services hereunder and Ventiv shall not backfill the respective position (a “Block Selection”) provided that: (i) such hiring may not occur prior to the first
anniversary of the Deployment Date and (ii) Iroko provides at least ninety (90) days prior written notice to Ventiv of any Block Selection. In the event Iroko wishes to implement a Block Selection, Iroko shall pay Ventiv a Conversion fee
based upon the date of the actual Block Selection, in accordance with the following: 
  

									
	 	  	Year One	  	Commencement of Year
Two until eighteen month
anniversary of
Deployment Date	  	Eighteen month
anniversary of
Deployment Date
until end of Year Two	  	After Year Two
					
	Ventiv Sales Representative Conversion Fee	  	No conversion permitted	  	[***]	  	[***]	  	[***]

  
 *** Portions of this page
have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission. 

  
 10 

 12.3 Iroko understands and agrees that Ventiv cannot guarantee that any Ventiv Sales
Representative will agree to participate in an Open Opportunity Hiring or Block Selection. Ventiv understands and agrees that Iroko is not obligated to hire Ventiv Sales Representatives, but will consider all qualified candidates for any open sales
representative positions. 
 12.4 In the event Iroko implements an Open Opportunity Hiring or Block Selection, the Parties agree
that any and all training materials made available to the Ventiv Sales Representatives will be immediately returned to Ventiv, it being understood and agreed that the Ventiv proprietary training modules constitutes valuable and proprietary
information of Ventiv and is subject to the confidentiality obligations set forth in Section 10, above. Within five (5) days of implementing an Open Opportunity Hiring or Block Selection in which a Ventiv Sales Representative is selected,
Iroko shall return to Ventiv any originals and copies of the Ventiv proprietary training modules which had been in possession of the selected Ventiv Sales Representatives 
 12.5 In the event Iroko conducts an Open Opportunity Hiring or Block Selection (collectively, a “Selection”) and the selected Ventiv Sales Representative had been provided with use of a fleet
automobile leased, rented or owned by Ventiv and Iroko wishes to commence an arrangement with the fleet vendor to assume such cars (and all associated costs and liabilities) under Iroko’s name, the selected Ventiv Sales Representative may only
continue to have access to such automobile following the Selection if Iroko either: (i) registers the fleet automobile under its name; or (ii) ensures that Ventiv remains named as an additional insured under Iroko’s automobile
insurance policies until such time as the vehicle is registered in Iroko’s name (which shall occur no later than three (3) months following the Selection). The Parties understand and agree that it is solely Iroko’s obligation to
ensure one of the above actions are taken and Iroko shall be responsible for indemnifying defending and holding Ventiv harmless for all damages resulting from Iroko’s failure to take such action. The Parties further agree that on the effective
date of the Selection, Iroko shall destroy the Ventiv insurance card(s) in the fleet vehicle(s) of the selected Ventiv Sales Representative. 
 12.6 Upon any selection under this Section 12, the parties will meet and discuss in good faith the impact of such selection on any applicable risk metrics. 

  
 11 

 13. Records; Reports; Notifications; Regulatory Inquiries; Audits 

13.1 Records. Ventiv shall keep and maintain, during the term of this Agreement and for a period of three (3) years
thereafter, complete and accurate records relating to the Services and Project Items provided under this Agreement. 
 13.2
Reports. Ventiv shall provide Iroko with the periodic reports described in Exhibit A attached hereto and at the frequency set forth herein. 
 13.3 Notifications. Ventiv shall notify Iroko within twelve (12) hours if Ventiv receives any information that relates, refers or pertains to an adverse event, a technical complaint relating
to any Iroko Product or any report of any other problem involving any Iroko Product (e.g., contamination, discoloration, improper labeling, adulteration, etc.). Ventiv shall notify Iroko promptly if Ventiv receives any information that relates,
refers or pertains to the initiation of any investigation, claim, lawsuit or other proceeding against Ventiv that relates to the Services, Project Items or Iroko Product or any Ventiv personnel in their role providing Services hereunder. 

13.4 Regulatory Inquiries. Ventiv shall notify Iroko immediately following receipt of any request for information by any regulatory
authority regarding Iroko, the Services, Project Items or Product, and shall permit representatives of Iroko to assist Ventiv in the preparation of a response. Further, Ventiv shall permit representatives of the Food and Drug Administration
(“FDA”) or Drug Enforcement Agency or their agents to visit and inspect and audit any and all records, documents, or facilities related to or used in the promotion, sale and/or sampling of Iroko Product and will promptly provide Iroko with
prior written notice of such visit, inspection, and/or audit. 
 13.5 Audit. During the term of this Agreement and for a
period of one (1) year thereafter, upon reasonable prior written notice and during normal business hours, Iroko shall be entitled to inspect and audit, directly or through a third party all books and records of Ventiv, at Iroko’s sole
expense, which are maintained by Ventiv in connection with the Services provided under this Agreement. In addition, Iroko shall have the right, during the terms of this Agreement, to inspect Ventiv’s facility, during normal business hours, upon
reasonable prior written notice and at Iroko’s sole expense. Notwithstanding the foregoing or anything to the contrary herein, Iroko may audit Ventiv for cause during normal business hours and at Iroko’s sole expense upon reasonable prior
written notice. 
 14. Property Rights. 
 14.1 Exclusive Rights. Iroko shall retain all rights in any data, works, materials and intellectual and other property provided by Iroko to Ventiv and its personnel. No licenses, express or
implied, are granted by Iroko under this Agreement. 
 14.2 Works-for-Hire. All deliverables and other data, reports,
works of authorship, inventions (whether reduced to practice or not), know-how, software, improvements, designs, devices, inventions (whether or not patentable), processes, methods, products 

  
 12 

 
and other work product developed, authored, conceived, produced or acquired by Ventiv or any of its personnel pursuant to this Agreement (the “Work Product”) shall be deemed “works
made for hire” and shall be the exclusive property of Iroko. To the extent that any of the Work Product may not, as a matter of law, be deemed a work made for hire, Ventiv hereby assigns to Iroko all right, title and interest in the Work
Product. Ventiv shall execute and deliver any documents and do such things as may be necessary or desirable in order to carry into effect the provisions of this Section 14. All Work Product shall be deemed the Confidential Information of Iroko.

 14.3 General Expertise. Iroko acknowledges that Ventiv’s ability to perform the Services is dependent on
Ventiv’s past experience in providing similar service to others, and that Ventiv expects to continue such work in the future. Ventiv retains and is not conveying to Iroko its methods of business or operation or expertise relating to services
that it provides. Further, to the extent any Work Product or work made for hire include Ventiv’s concepts, ideas, models, know-how, software, methodologies, technology, techniques, procedures, management tools, workshops, manuals, macros, data
files, inventions, and other intellectual capital and property that Ventiv has developed, created or acquired prior to, in the course of, or independent of performing Services under this Agreement (the “Ventiv Materials”), Ventiv shall
retain exclusive ownership in such Ventiv Materials. Ventiv hereby grants Iroko a non-exclusive, fully paid up, perpetual, non-transferable, royalty-free right and license, for it to use the Ventiv Materials solely in connection with its use of the
deliverables created by Ventiv in connection with the Services. 
 14.4 Trademarks. Ventiv shall use Trademarks in
connection with performance of the Services. Nothing in this Agreement shall be deemed to give Ventiv my rights, title or interest in or to any Trademarks. Ventiv shall not, or knowingly cause another third party to, contest or dispute or otherwise
impair or endanger the validity of, or the exclusive rights of Iroko of its Affiliates in or to, any of the Trademarks. Ventiv acknowledges that all use of the Trademarks by or on behalf of Ventiv shall inure to the benefit of Iroko or its
Affiliates. Ventiv shall not be entitled to any compensation for any increase in the value of the Trademarks or in the goodwill associated therewith. Ventiv, upon written request by Iroko, shall provide reasonable assistance to Iroko or its
Affiliates to safeguard their Ml rights, title and interest in and to the Trademarks. Ventiv shall promptly advise Iroko of all cases of actual, potential or suspected infringement of the Trademarks that came to Ventiv’s attention and shall
render assistance reasonably requested in connection with any action taken by Iroko. 
 15. Non-Competition; Non-Solicitation.

 15.1 Non-Competition. For so long as Ventiv is providing Services under this Agreement and for a period thereafter
equal to lesser of either (i) the actual length of time of the term of this Agreement; or (ii) one (1) year thereafter, Ventiv shall not, directly or indirectly, assign the National Business Director: 

15.1.1. market, promote, present, sell or accept orders for the sale of any Competing Products in the Territory; or 

15.1.2. assist or cooperate with any third party in connection with the marketing, promotion, presenting, selling or acceptance of orders
for the sale of any Competing Product in the Territory. 

  
 13 

 15.2 Limitations Reasonable. Ventiv acknowledges that the temporal and geographic
limitations set forth in this Section 15 are reasonable and necessary to protect the legitimate interests of Iroko and agrees not to contest such limitations in any proceeding. The period of time during which Ventiv is prohibited from engaging
in certain activities pursuant to the terms of this Section 15 shall he extended by the length of time during which Ventiv is in breach of any of the terms of this Section 15 as determined by any judicial or other legally binding
proceeding. 
 15.3 Injunctive Relief. Ventiv further acknowledges that the failure by Ventiv to comply with any of the
provisions of this Section 15 will result in irreparable injury and continuing damage to Iroko for which there will be no adequate remedy at law and that, in the event of a failure of Ventiv to so comply, Iroko shall be entitled to such
temporary, preliminary and permanent injunctive relief as may be proper and necessary to ensure compliance with all the provisions of this Section 15 without having to prove actual damages or to post a bond. 

15.4 Non-Solicitation. 
 15.4.1. Neither Party may solicit the employees or independent contractors of the other Party with whom they interact under this Agreement to become employees of, or consultants to, the other Party during
the Term of this Agreement and any SOW for a one (1) year period following the termination of both this Agreement and any SOW. The provisions of this Section 15.4 shall not apply with respect to either Party’s employees or independent
contractors who seek employment from the other Party on their own initiative, such as, but not limited to, in response to a Party’s general vacancy announcement or advertisement. 

15.4.2. Iroko agrees during the Term of this Agreement and for one (1) year thereafter not: (i) to provide any contact
information (including name, address, phone number or e-mail address) of any Ventiv employee to any third party which provides or proposes to provide Iroko with the same services being provided by Ventiv pursuant to this Agreement or any related
SOW, or (ii) to assist actively in any other way such a third party in employing or retaining such Ventiv employee. Iroko shall pay or cause the third party to pay Ventiv $25,000 for each Ventiv employee so employed or retained as liquidated
damages for breach of this Section 15.4.2. The provisions of this Section 15.4 shall not apply to Conversions made pursuant to Section 12 hereof. 

  
 14 

 16. Management of the Relationship. 

16.1 The Patties will establish a joint committee that will be the policy and final decision body to manage the business relationship
between the parties with regards to Iroko Product (the “Steering Committee”). In addition, the Parties will establish an operational team to manage day to day operational issues and decisions relating to the Services (the “Operational
Team”). 
 16.2 The Steering Committee shall not have more than eight (8) members and shall comprise an equal number of
members from both Iroko and Ventiv, provided, however, that each party must have on the Steering Committee, employees/officers with functional representation in the following areas: (i) Sales, (ii) Compliance, and (iii) Business
Development/Alliance Management. The Steering Committee shall meet at least once every other month face-to-face unless a greater frequency is agreed by both Parties, and at a minimum once a year face-to-face. 

16.3 The Operational Team shall consist of the Iroko VP of Sales or designee and Ventiv National Business Director or designee and shall
meet preferably face-to-face at least once every two weeks at the discretion of the Operational Team throughout the term of this Agreement. Issues that are not resolved by the Operational Team shall be escalated to the Steering Committee for
resolution. 
 17. Indemnification. 
 17.1 Ventiv. Ventiv shall indemnify and hold Iroko, its officers, directors, agents and employees harmless from and defend against any and all third party liabilities, losses, proceedings, actions,
damages, claims or expenses of any kind, (including, but not limited to, court costs and reasonable attorneys’ fees) (collectively “Claims”) arising out of or in connection with: (i) any negligent or reckless acts or omissions or
acts or omissions amounting to willful misconduct by Ventiv, its agents, directors, officers, or employees or acts outside the scope of their duties in performing the Services (except to the extent the actor was following the instructions of Iroko
or its representatives), or (ii) my material breach of this Agreement or my related SOW by Ventiv, its agents, directors, officers or employees. 
 17.2 Iroko. Iroko shall indemnify and hold Ventiv, its officers, directors, agents, and employees harmless from and defend against any and all Claims arising out of or in connection with:
(i) any negligent or reckless acts or omissions, or willful misconduct by Iroko, its agents, directors, officers or employees, (ii) any material breach of this Agreement or any related SOW by Iroko, its agents, directors, officers, or
employees, (iii) Iroko Product liability claims, whether arising out of warranty, negligence, strict liability (including manufacturing, design, warning or instruction claims) or any other product based statutory claim, but excluding any claims
for which Ventiv indemnifies Iroko under this Agreement or (iv) any intellectual property infringement claims relating to any trademarks owned by or licensed to Iroko. 

  
 15 

 17.3 Procedure. In case any action, proceeding or claim shall be brought against one
of the parties hereto (an “Indemnified Party”) based upon any of the above Claims and in respect of which indemnity may be sought against the other party hereto (the “Indemnifying Party”) such Indemnified Party shall promptly
notify the Indemnifying Party in writing. The failure by an Indemnified Party to notify the Indemnifying Party of such Claim shall not relieve the Indemnifying Party of responsibility under this Section 17, except to the extent such failure
adversely prejudices the ability of the Indemnifying Party to defend such claim. The Indemnifying Party at its expense, with counsel of its own choice, shall defend against, negotiate, settle or otherwise deal with any such claim, provided that the
Indemnifying Party shall not enter into any settlement or compromise of my claim which could lead to liability or create any financial or other obligation on the part of the Indemnified Party without the Indemnified Party’s prior written
consent. The Indemnified Party may participate in the defense of any claim with counsel of its own choice and at its own expense. The parties agree to cooperate fully with each other in connection with the defense negotiation or settlement of any
such claims. In the event that the Indemnifying Party does not undertake the defense, compromise or settlement of any claim, the Indemnified Party shall have the right to control the defense or settlement of such claim with counsel of its choosing.
Notwithstanding the foregoing, Iroko shall fully control any defense relating to Iroko Product liability claims. 
 17.4 Iroko
shall reimburse Ventiv for all reasonable actual out-of-pocket expenses incurred by Ventiv in connection with responses to subpoenas and other similar legal orders issued to Ventiv in respect to Iroko’s Products or the Services performed under
this Agreement and any related SOW. However, Iroko shall have no obligation to reimburse Ventiv for my such expenses arising out of, in connection with or otherwise relating to actions or omissions of Ventiv or its employees, officers, directors
and/or Affiliates feat violate this Agreement or Applicable Law. 
 17.5 Ventiv shall reimburse Iroko for all reasonable actual
out-of-pocket expenses incurred by Iroko in connection with responses to subpoenas and other similar legal orders issued to Iroko in respect to Ventiv’s services generally and where Ventiv is the investigation target. However, Ventiv shall have
no obligation to reimburse Iroko for any such expenses arising out of, in connection with or otherwise relating to actions or omissions of Iroko or its employees, officers, directors and/or Affiliates that violate this Agreement or Applicable Law.

  
 16 

 18. Insurance. 
 18.1 Ventiv. 
 18.1.1. During the term of this Agreement and for so long as
Ventiv is performing the Services hereunder, Ventiv shall maintain insurance coverage as follows: 
  

					
	Policy	  	Limits	  	Coverage
	Comprehensive General Liability	  	$1,000,000 per occurrence and $2,000,000 per year (with a deductible or SIR up to $50,000)	  	Coveting bodily injury, personal injury, property damage, including without limitation all contractual liability for such injury or damage assumed by Ventiv under this
Agreement.
			
	Worker’s Compensation	  	$1,000,000 (except in States which require purchase of state insurance plan coverage; in those States, the policy limits are those provided by the State Plan)	  	In accordance with all federal, state, and local requirements.
			
	Umbrella Liability	  	$3,000,000 per occurrence and $3,000,000 per year	  	
			
	Errors and Omissions Liability	  	$1,000,000 per occurrence and $3,000,000 per year (with a deductible or SIR up to $1,000,000)	  	
			
	Automobile Liability	  	$1,000,000 per occurrence for vehicles owned, leased, or rented by Ventiv	  	Commercial automobile liability insurance.

 18.1.2. Except as set forth in Section 18.1.3, below, Iroko, and its directors, offices, employees,
agents, subsidiaries and Affiliates shall be named as additional insured, as their interest may appear, on a primary, non-contributory basis under each such policy of insurance obtained by Ventiv. All of the foregoing policies shall be issued by a
recognized insurer rated “A-VII” or better by a recognized and reputable rating agency. These insurance provisions set forth the minimum amounts and scopes of coverage to be maintained by Ventiv and shall not be construed in any way as a
limitation on Ventiv’s liability under this Agreement. Where there is an indemnity obligation under this Agreement, the insurance coverages shall be primary and will not participate with nor will be in excess of any valid and collectable
insurance or program of self-insurance carried or maintained by Iroko. Each Party shall furnish the other Party with certificates of insurance evidencing all of the insurance coverage specified in this Section 18 within thirty (30) days of
execution of this Agreement. In the event that any Services under this Agreement are to be rendered on behalf of Ventiv by individuals other than Ventiv’s own employees, Ventiv shall arrange for such individuals to forward to Iroko, prior to
commencement of services by them, certificates of insurance evidencing such amounts, in such form, and with such insurance companies as are satisfactory to Iroko. 

  
 17 

 18.1.3. Iroko shall carry product liability insurance in the amount of at least Ten (10)
Million dollars, subject to the good faith review and appropriate increase upon the launch of the Products, Each Party shall name the other Party as an additional insured on all liability insurance coverage with the exception that Ventiv will not
name Iroko as an additional insured nor extend its Products Liability, Errors & Omissions/Professional Liability or its Employment Practices Liability insurance to Iroko. 
 19. Term and Termination. 
 19.1 Term. The term of this Agreement
shall commence as of the Effective Date and unless earlier terminated in accordance with the terms hereof, shall continue in effect for two (2) years from the Deployment Date (the “Term”). The period from the Deployment Date until the
day prior to the one year anniversary of the Deployment Date shall be referred to herein as “Year One” and the period from the one year anniversary of the Deployment Date through the day prior to the second anniversary of the Deployment
Date shall be referred to herein as “Year Two”. This Agreement will renew for additional periods of one year each (each an “Additional Term”), upon written agreement by the Parties to be executed at least ninety (90) days
prior to the end of the Term or the Additional Term as the case may be. The compensation to Ventiv for any Additional Term must be agreed upon and set forth in the written agreement between the Parties. 

19.2 Termination for Convenience. Either Party may terminate this Agreement at any time for any reason upon ninety (90) days
prior written notice to the other Party; provided, however, that the actual termination date may not occur prior to the one year anniversary of the Deployment Date. 
 19.3 Termination For Breach. This Agreement may be terminated by either party if the other party has breached any material term or condition of the Agreement and such breach remains uncured for
sixty (60) days following written notice from the non-breaching party specifying the breach. 
 19.4
Bankruptcy/Insolvency. This Agreement may be terminated by either party, on ten (10) days notice to the other party, if the other party makes an assignment for the benefit of creditors, files a petition in bankruptcy, is adjudicated
insolvent or bankrupt, if a receiver or trustee is appointed with respect to a substantial part of such other party’s property or a proceeding is commenced against it which will substantially impair its ability to perform hereunder. 

19.5 Termination for Late Payment: Failure to Pay. Ventiv may terminate this Agreement or any related SOW, if any undisputed
payment to Ventiv by Iroko is not made when due and such payment is not made within fifteen (15) days from the date of written notice from Ventiv to Iroko of such nonpayment. 

  
 18 

 19.6 Effect of Expiration or Termination. 

19.6.1. Ventiv’s Duties. Upon expiration or termination of this Agreement, Ventiv shall: 

(i) assist Iroko by performing all reasonably requested tasks in the decommissioning and transitioning of the applicable Services to
Iroko or Iroko’s designee to ensure a smooth transition and uninterrupted provision of the Services including, but not limited to continuation of applicable Services pursuant to the terms of the Agreement for up to ninety (90) days and
referring to Iroko or its designee of all inquiries relating to Iroko, the applicable Services and the applicable Project Items; 
 (ii) except to the extent set forth above, (a) immediately cease performance of Services, (b) ensure that all Confidential Information, Project Items, Work Product, building passes,
identification badges, electronic data kept in Ventiv’s systems and any other property of Iroko in Ventiv’s possession or control is returned to Iroko, (c) take all reasonable steps to minimize costs relating to such termination;

 (iii) provide to Iroko a list of all Ventiv personnel fully dedicated to providing the Services and Iroko or its designee
shall be entitled, with the cooperation of Ventiv, to offer employment or a consulting engagement to some or all of such personnel, subject to any additional terms set forth in the applicable Task Orders. The Parties agree and acknowledge that this
list and any information pertaining to such personnel shall be deemed not to be Confidential Information of Ventiv and shall not constitute an offer of employment to such personnel, and that Iroko shall have no obligation to offer employment to such
personnel; and 
 (iv) at Iroko’s request, transfer and deliver to Iroko all equipment (e.g., fleet automobiles, laptops,
iPads, etc. (collectively “Equipment”) that Iroko has paid for as a pass-through expense. Where lessor consent is required, Ventiv will endeavor to negotiate lessor consent at the time of leasing. 

19.6.2. Iroko’s Duties. Upon expiration or termination of this Agreement, Iroko shall: 

(i) pay for services rendered through the date of termination or expiration; 

(ii) In the case of termination of this Agreement or any related SOW by Iroko (except for termination by Iroko pursuant to Section 19.2
or 19.3, or at the end of the Term (or any Additional Term), or in the event Iroko conducts a Conversion (as set forth in Section 12 above), Iroko shall (in 

  
 19 

 
addition to all other payment obligations under this Agreement) promptly pay (or if paid by Ventiv, promptly reimburse) Ventiv for: the amount due any lessor or rental agent of the Equipment
leased or owned by Ventiv and provided to members of the Project Team, for any early termination (excluding termination under Sections 19.2 or 19.3) of the lease or rental agreement. In addition, Iroko may elect to either: (i) in the event the
Equipment is owned by Ventiv, transfer the Equipment to Iroko and pay an amount equal to the net book value (if any) of the Equipment on the books of Ventiv at the time of the transfer event, or in the event the Equipment is subject to a lease or
finance lease, the Equipment may be transferred to Iroko (subject to the last sentence of this Section 19.6.2(ii)) and Iroko shall assume the responsibility for all further payments due (including costs associated with the transfer), or
(ii) pay Ventiv the net loss to Ventiv on such Equipment determined by the difference between the net book value of such Equipment and the actual net price received by Ventiv for the disposal of such Equipment, plus any amounts due by Ventiv in
connection with the lease or rental termination and costs associated with the storage and disposal of said Equipment Any proposed transfer of Equipment to Iroko shall be subject to Iroko establishing its own relationship and credit with the entity
that Ventiv contracted with to lease or rent such Equipment; and 
 (iii) In the event of termination by Iroko pursuant to
section 19.2 or by Ventiv pursuant to section 19.3 or 19.4, any risk metric based on sales of a Product shall be paid by Iroko to Ventiv for the then current period on a prorated basis at the greater of (i) 100% of sales target; or
(ii) the actual sales trend at the time of termination. 
 19.7 Survival. Expiration or termination of this Agreement
shall not relieve either party of any obligation or liability accrued prior to the termination date. The obligations of the parties set forth in Sections 9, 10, 13, 14, 15, 17, 18, 19, 20, 21, and 22 of this Agreement shall survive expiration or
early termination of this Agreement. 
 20. Representations and Covenants. 

20.1 Mutual. Each party represents and covenants to the other that (i) as of the Effective Date it has full right, power and
authority to enter into this Agreement, (ii) this Agreement has been duly executed by such party and constitutes a legal, valid and binding obligation of such party, enforceable in accordance with its terms and (iii) it does not now have,
and will not during the term of this Agreement have, any obligations or other commitments to a third party that might interfere with its obligations hereunder. 
 20.2 By Ventiv. Ventiv covenants, represents, and warrants that: 
 20.2.1.
it shall perform, and shall require that all Sales Representatives to perform, all Services in a professional, workmanlike manner consistent with industry standards and in conformance with that level of care and skill ordinarily

  
 20 

 
exercised by other competent professional contract service organizations in similar circumstances and in accordance with those specifications and timelines set forth herein. Ventiv shall ensure
that its employees or agents complete the Services in a timely manner and in accordance with the terms of this Agreement; 

20.2.2. the Ventiv Sales Representatives shall not be permitted to add, delete or modify claims of efficacy or safety of the Product, nor
make any changes (including but not limited to, underlining or otherwise highlighting any language or adding any notes thereto) in the Product Literature. Ventiv shall only use and shall permit the Ventiv Sales Representatives to only use the
Product Literature provided by Iroko. Ventiv and the Ventiv Sales Representatives shall not develop, create, or use any other promotional material or literature or alter Product Literature provided by Iroko. Ventiv shall immediately cease the use of
any Product Literature when instructed to do so, in writing, by Iroko. Ventiv shall use the Product Literature only for the purposes of this Agreement; 
 20.2.3. it shall not, and shall not permit Ventiv Sales Representatives to, directly or indirectly, pay, offer or authorize payment of anything of substantial value (either in the form of compensation,
gift, contribution or otherwise) to any person or entity in a position to order or purchase the Product contrary to any law; 

20.2.4. it shall not, and shall not permit the Ventiv Sales Representatives to, directly or indirectly, make any representations or
warranties relating to Iroko Product that conflict, or are inconsistent with the FDA approved labeling for the Iroko Product; 

20.2.5. it shall require that each Ventiv Sales Representative promote, market and sell Iroko Product as well as distribute samples in
accordance with Applicable Law 
 20.2.6. neither it nor the Work Product will violate, infringe or misappropriate any right or
legally protected interest of any person or entity; 
 20.2.7. it has obtained and will maintain all releases, permissions and
licenses necessary for Iroko to perform the Services; 
 20.2.8. it shall implement appropriate physical and technological
measures to prevent Confidential Information of Iroko from being disclosed to or accessed by third parties; and 
 20.2.9. any
computer systems provided by Ventiv and used in connection with the Services will (i) operate substantially in accordance with any descriptions or specifications set forth in this Agreement or otherwise published by Iroko and (ii) be
available without interruption, except for any scheduled down time needed to maintain the effective operation of such systems and when interruptions are caused by conditions outside of Ventiv’s reasonable control. 

  
 21 

 20.3 By Iroko. Iroko covenants, represents, and warrants that: 

20.3.1. it recognizes that for Ventiv to comply with its obligations hereunder, it shall need the good faith cooperation of Iroko to
provide Ventiv with the necessary materials and assistance required to enable Ventiv to perform the Services; 
 20.3.2. the
Services being provided by Ventiv are in furtherance of Iroko’s program of marketing and promoting Iroko Product and as such, Iroko is responsible for ensuring, and further, Iroko represents and warrants, that Iroko’s program is being
implemented by Vastly pursuant to the terms hereof (but not the implementation thereof by Ventiv), adheres to Applicable Law; 

20.3.3. it shall ensure that none of its employees working with the Project Team or in connection with the Services, directly or
indirectly instruct any Ventiv employee to pay, offer or authorize payment of anything of substantial value (either in the form, of compensation, gift, contribution or otherwise) to any person or entity in a position to order, recommend or purchase
the Product contrary to any law; 
 20.3.4. neither it nor any of its employees directly or indirectly instruct any Ventiv
employee to make any representations or warranties relating to the Product that conflict, or are inconsistent with applicable laws or the FDA approved labeling for the Product; and 

20.3.5. The Project Items provided to Ventiv for use in providing the Services will not violate, infringe, or misappropriate any right or
legally protected interest of any person or entity and shall comply with Applicable Law. 
 20.4 Disclaimer of Warranty.
EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, EACH PARTY DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY WARRANTIES OF MERCHANTABILITY, TITLE, FITNESS FOR ANY PARTICULAR PURPOSE AND NON-INFRINGEMENT. 

  
 22 

 21. Limitation of Liability. IN NO EVENT SHALL ANY PARTY BE LIABLE FOR LOST PROFITS, OR ANY INDIRECT,
SPECIAL, INCIDENTAL, CONSEQUENTIAL, OR SIMILAR DAMAGES (COLLECTIVELY “CONSEQUENTIAL DAMAGES”), HOWEVER CAUSED AND ON ANY LEGAL THEORY, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. THE LIMITATIONS OF THIS SECTION
SHALL NOT LIMIT A PARTY’S INDEMNIFICATION OBLIGATIONS OR LIABILITY FOR BREACH OF ITS CONFIDENTIALITY OBLIGATIONS. IN ADDITION, THE TOTAL LIABILITY OF VENTIV TO IROKO FOR CONSEQUENTIAL DAMAGES RELATING TO BREACH OF ITS CONFIDENTIALITY
OBLIGATIONS SHALL BE LIMITED TO THE TOTAL FEES ACTUALLY PAID BY IROKO TO VENTIV FOR SUCH SERVICES GIVING RISE TO THE CLAIMS DURING THE ONE (1) YEAR PERIOD IMMEDIATELY PRECEEDING THE EVENT GIVING RISE TO THE CLAIM. 

22. Miscellaneous. 
 22.1
Authority to Contract. Each Party represents to the other that the execution, delivery and performance of this Agreement by such Party has been duly authorized by all requisite corporate action; that the Agreement constitutes the legal,
valid, and binding obligation of such Party, enforceable in accordance with its terms (except to the extent enforcement is limited by bankruptcy, insolvency, reorganization or other laws affecting creditors’ rights generally and by general
principles of equity); and that this Agreement and performance hereunder does not violate or constitute a breach under any organizational document of such Party or any contract, other form of agreement, or judgment or order to which such Party is a
party or by which it is bound. 
 22.2 Assignment. Neither Ventiv nor Iroko may assign this Agreement or any of its
rights, duties or obligations hereunder or subcontract to others without the other Party’s prior written consent, such consent not to be unreasonable withheld, provided, however, that either Ventiv or Iroko may assign its rights, duties and
obligations as part of an acquisition of Ventiv or Iroko, as the case may be, so long as the acquirer (i) is a financially capable business entity, (ii) expressly assumes in writing those rights, duties and obligations under this Agreement
and this Agreement itself and (iii) is not a competitor of the other Party. 
 22.3 Force Majeure. Noncompliance with
the obligations of this Agreement due to a state of force majeure, the laws or regulations of any government, regulatory or judicial authority, war, civil commotion, destruction of facilities and materials, fire, flood, earthquake or storm, labor
disturbances, shortage of materials, failure of public utilities or common carriers, and any other causes beyond the reasonable control of the applicable Party, shall not constitute a breach of contract. 

22.4 Severability. If any provision of this Agreement is finally declared or found to be illegal or unenforceable by a court of
competent jurisdiction, both Parties shall be relieved of all obligations arising under such provision, but, if capable of performance, the remainder of this Agreement shall not be affected by such declaration or finding. 

  
 23 

 22.5 Notices. Any notices required or permitted under this Agreement shall be given
in person or sent by first class, certified mail to: 
 Ventiv: 

Ventiv Commercial Services, LLC 
 500 Atrium Drive 
 Somerset, New Jersey 08873 

Attention: President, VCS 
 with a copy to: 
 Ventiv Commercial Services, LLC 

500 Atrium Drive 

Somerset, New Jersey 08873 
 Attention: VCS General Counsel 
 Iroko: 

Iroko Pharmaceuticals LLC 
 One Kew Place 
 150 Rouse Boulevard 

Philadelphia, PA 19112 
 Attention: President & CEO 
 with a copy to: 

Iroko Pharmaceuticals LLC 
 One Kew Place 
 150 Rouse Boulevard 

Philadelphia, PA 19112 
 Attention: General Counsel 
 or to such other address or to such other person as
may be designated by written notice given from time to time during the term of this Agreement by one Party to the other. 
 22.6
Amendments. This Agreement may be modified or amended only by a written instrument that specifically references this Agreement and is signed by a duly authorized representative of each of the Parties. 

22.7 Third Parties. Except as otherwise provided herein, nothing in this Agreement shall confer any benefits or rights on any
person or entity other than the Parties to this Agreement. 

  
 24 

 22.8 Waiver. No delay or omission by either party to exercise any right or remedy
under this Agreement shall be construed as a waiver of such right or remedy. Any waiver of any term or condition of this Agreement must be in writing and signed by both Parties hereto. A waiver of any term or condition hereof shall not be construed
as a future waiver of that or any other term or condition. 
 22.9 Entire Agreement. This Agreement, which includes and
incorporates all Exhibits attached hereto, constitutes the entire agreement of the parties with respect to the subject matter hereof Any and all prior negotiations, representations, communications, agreements and understandings between the Parties
with respect to the subject matter hereof ere superseded hereby. Neither Party has entered into this Agreement in reliance on any representation or covenant of the other Party not fully set forth herein. 

22.10 Governing Law; Forum. This Agreement and all claims related to it, its execution or the performance of the Parties under it,
shall be construed and governed in all respects according to the laws of the Commonwealth of Pennsylvania, without regard to the conflict of law provisions thereof. Any actions arising hereunder shall be brought solely and exclusively in the federal
or state courts sitting in the Commonwealth of Pennsylvania, and each Party hereby consents to the sole and exclusive jurisdiction and venue of such courts with regard to such actions. 

22.11 Execution in Counterpart. For the convenience of the Parties, this agreement may be executed in counterparts and by facsimile
or email exchange of pdf signatures, each of which counterpart shall be deemed to be an original, and both of which taken together, shall constitute one agreement binding on both Parties. 
 WHEREFORE, the parties hereto have caused this Agreement to be executed by their duly authorized representatives. 
  

					
	VENTIV COMMERCIAL SERVICES, LLC
		
	By:	 	

		 	Name:	 	Paul Mignon
		 	Title:	 	President
	
	IROKO PHARMACEUTICALS LLC
		
	By:	 	

		 	Name:	 	JOHN VAVRICKA
		 	Title:	 	PRESIDENT & CEO

  
 25 

 EXHIBIT A 
 SERVICES 
 Ventiv Sales Representatives shall exclusively promote and sell
Iroko Product and distribute Iroko Product Samples and Product Literature to Health Care Professionals. Ventiv Sales Representatives shall report to the Project Team that will liaison with Iroko Regional Business Managers who will be recruited by
Iroko five to six months in advance of the Deployment Date and with adequate time to provide input regarding Ventiv Sales Representatives recruiting. 
  

	I.	RECRUITING 

 Ventiv shall
recruit and hire up to 350 full-time Ventiv Sales Representatives to commence providing Services on or about the Sales Representative Start Date and may add additional Sales Representatives in [***]. Ventiv shall provide the Ventiv Sales
Representatives with salary, benefits, fleet automobiles, handheld PDA’s, laptop computers and iPads (including sales force automation software) and printers. The average bonus of the Sales Representatives shall be no more than [***] of base
salary and shall be strictly in accordance with the Incentive Compensation Plan as approved by Iroko. 
 Ventiv shall recruit
and keep the requisite number of positions required for Ventiv Employee Relations Managers to the manageable minimum. Iroko anticipates a ratio of one Ventiv Employee Relations Manager to 2-3 Iroko Regions, during the initial implementation period
which shall end 90 days following launch. After the initial implementation period, the ratio shall be 1 Employee Relations Manager for every 4 Iroko Regions (assuming ten Ventiv Sales Representatives per Region). Ventiv shall adjust proposals to
reflect this position and propose alternatives to facilitate a seamless launch of Iroko’s products into the Territory. 

Ventiv warrants, represents and covenants that, as of the Sales Representative Start Date, 96% of defined territories will be either
filled with qualified Ventiv Sales Representatives or acceptance letters are in place from qualified candidates. This metric will be linked to a performance related target that impacts the management fee as set forth in Exhibit B. Ventiv shall
present to Iroko 2-3 qualified Sales Representative candidates per Sales Representative Territory opening [***] [***] [***] [***] [***] [***] Iroko recognizes that to meet this goal, Ventiv will begin recruiting efforts 60 days prior to the Sales
Representative Start Date (the “Recruiting Start Date”) and the costs of such will be paid for by Iroko pursuant to Exhibit B. 
 Should any vacancies arise, Ventiv shall warrant that any vacant Sales Representative Territories are backfilled by qualified Ventiv Sales Representatives, ready for their first day of training, within
[***] [***] business days of a vacancy coming up. Iroko’s Regional Business Manager will be readily available to review the candidates on a good faith basis and to provide comments regarding the candidates. 

  
 *** Portions of this page
have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission. 

  
 Exhibit –
Page 1 

	 	A.	VENTIV SALES REPRESENTATIVES HIRING 

 In selecting Ventiv Sales Representatives, Ventiv will use the guidelines below as a minimum standard. Ventiv will take reasonable steps to confirm the accuracy of information concerning background and
experience received from applicants for positions of Sales Representatives. Ventiv shall not knowingly employ or otherwise retain, or permit to be retained as a Sales Representative, a practicing physician or a person affiliated on a professional
level with or employed by any physician, physician practice or other healthcare professional or provider or a person who is in a position to unduly influence the purchase of Iroko Product. 

Eligibility 
 Must have: 
 4 year college degree 

Valid US Driver’s License 
 Outside sales experience 
 Dedication to full time employment 

Clearance on all pre-employment screening 
 Ability to attend required training programs 
 Ability to participate in minimal
overnight travel 
 Business Experience Preferences 

Most preferable to least preferable: 
 2-4 year’s Pharmaceutical sales experience 
 Healthcare sales experience in
NSAID or related pain management areas 
 Business to Business sales experience 

Documented track record of sales experience 
 Other outside sales experience 
 Teaching/coaching experience 

Professional Skills 
 Desired: 
 Professional image 

Oral and written communication skills 
 Listening skills 
 Technical/computer skills 

Achievement oriented 
 Well organized/disciplined 
 Competitive/industrious 

Self-motivated/performance accountability 
 Sense of urgency 
 Empathetic/Rapport builder 

Territory operational skills/time management 

  
 Exhibit –
Page 2 

	 	B.	PRE-SCREEENING 

Ventiv shall be responsible for performing drug testing and background checks of all Ventiv Sales Representatives. Ventiv
represents and warrants that it will complete or cause to be completed a thorough background check of all Ventiv Sales Representatives. This will include, Criminal Convictions Check, Social Security Check, Drug Screen, Motor Vehicle Record Check,
Education Check, Past Employer Verification subject to compliance with state and other laws. Ventiv further represents and warrants that it will perform or cause to be performed background checks to confirm that no Ventiv Sales Representative:

 i) is an excluded person on the Office of Inspector General’s List of Excluded Individuals/Entities and is not on the
General Services Administration Excluded Parties List (as of the date the background check is performed); 
 ii) is, so far as it
is aware, an unfit or an improper individual for the performance of the Services; 
 iii) is, so far as it is aware, engaged in
any fraudulent or unlawful activity, or other inappropriate conduct as measured by the other requirements of this Agreement 
  

	II.	TRAINING 

 The training
responsibilities of the Parties are as follows: 
 A. Ventiv shall be responsible for training all of the professional Sales
Representatives concerning: Ventiv human resource policies, procedures and administration and other applicable Ventiv internal human resource and general compliance policies and procedure as well as product training as set forth in Section C herein.
Minimum training requirements are set forth in attached Appendix A-l. 
 B. Iroko shall be responsible for training members of
the Project Team concerning all Product specific information including Product complaint handling procedures, applicable specific Iroko health care compliance policies and Iroko customer service policies and procedures, orientation to Iroko’s
business, compliance with Applicable Law, and adverse event reporting policies and procedures. The Parties agree to work together to mutually determine if when, and at what cost additional training shall be provided to members of the Project Team.

 C. Ventiv shall be responsible for providing a best in class selling skills training plan for the Sales Representatives which
shall include, without limitation, the following training: selling skills, role playing, effective customer need’s assessment and questioning skills, patient case studies, harassment, adverse events reporting, promotional regulations, PDMA and
OIG compliance. Iroko will be responsible for providing product and market specific curriculum to be delivered through Ventiv’s Learning, Management System (LMS) to the Sales Representatives and Iroko Regional Business Managers. 

  
 Exhibit –
Page 3 

 D. Ventiv shall ensure all Sales Representatives are fully trained and certified by launch
utilizing a combination of home study and class room certification. We expect that Sales Representatives would have gone through at least 1 week of home study and 1 week of classroom instruction with requisite testing prior to the launch meeting.
Requisite pass rates should be 90% of test scores and if any Sales Representative fails the same subject matter test twice, the Sales Representative shall be removed from the Iroko selling team. A Sales Representative who fails the test is allowed
to retake the test once within 5 business days. Ventiv shall be responsible for providing ongoing periodic training and certifications of the Sales Representatives based on the materials and reasonable standards provided by Iroko. 

E. Ventiv will train Iroko Regional Business Managers on the full training curriculum to be delivered to the Sales Representatives to
ensure continuity of knowledge and expected skill sets for coaching and development of the Sales Representatives. 
 F. Ventiv
will ensure the training and initial certification of all “backfill” Sales Representatives before they are active in the territory based on the materials and reasonable standards provided by Iroko. A written “backfill” training
plan shall be provided to Iroko for approval 
  

	III.	MEETINGS AND PERFORMANCE 

The meetings Iroko has agreed to are described in attached Appendix A-2. The length of training, launch and POA meetings shall be mutually
agreed to. Expenses associated with POA meetings and national training meetings and launch meetings shall be paid for by Ventiv as a pass-through expense to be direct billed to Iroko. 

 

	IV.	DUTIES 

  

	 	A.	CALLS 

 The Ventiv Sales
Representatives shall provide only Iroko approved Promotional Material, Product Literature and Product samples when making Calls. Sampling of the Product by Ventiv Sales Representatives shall be conducted in accordance with Exhibit C attached
hereto. Iroko is solely responsible for the content, production and distribution to Ventiv of the Promotional Material and Product Literature. Each Ventiv Sales Representative shall record information concerning each Call, including but not limited
to Product sample distribution, and concerning the profile of each individual Target (or other Health Care Professional called upon) on whom the Ventiv Sales Representative calls. Product sampling shall be done in accordance with guidance provided
by Iroko in advance of the Sales Representative’s deployment. 

  
 Exhibit –
Page 4 

 1. Ventiv shall collectively deliver via the Sales Representative team a
minimum of [***]) of the required Sales Presentations (professional detail equivalents) for ZORVOLEXTM and TIFORBEXTM each, against the Call Plan to Iroko’s defined Target Health Cars Professionals during each POA period. Iroko expects
an average of [***] sales calls per day (80% to Target Health Care Professionals and 20% to allowable non-target Health Care Professionals). 
 2. Active Territory Days: Iroko has defined active territory days as [***] days/year. Ventiv sales team shall collectively meet or exceed a 95% threshold of delivering Sales Representatives active
territory days with the anticipation that there are [***] selling days in a complete calendar quarter. 

Additionally, each Ventiv Sales Representative will be responsible for executing various Iroko designed,
supported & funded customer programs in support of the overall promotional strategy. The number and type of customer programs will be mutually agreed to by both Ventiv and Iroko. 

If Iroko believes in good faith that the performance of any Ventiv Sales Representative is unsatisfactory or is not in
compliance with the provisions of this Agreement, Iroko shall notify Ventiv and Ventiv shall promptly address the performance or conduct of such person in accordance with Ventiv’s human resource policies. In the event that Iroko determines in
good faith that a Ventiv Sales Representative has violated any applicable law, regulation or policy, Iroko shall notify Ventiv in writing. Ventiv shall promptly address the issue and take all reasonable and appropriate action (including but not
limited to termination of such employee). 
  

	 	B.	CALL REPORTING 

 Ventiv shall
provide Iroko on a monthly basis with standard reports as set forth in Appendix A-3. 
  

	 	C.	INCENTIVE COMPENSATION PLAN FOR VENTIV SALES REPRESENTATIVES 

 Ventiv shall program, implement, administer and maintain an incentive compensation plan (the “IC Plan”) for the Ventiv Sales Representatives, subject to Iroko’s prior approval. 

 

	 	D.	COMPLIANCE MONITORING PLAN 

Ventiv and Iroko shall develop a written Compliance Monitoring Plan for the effective monitoring of the Sales Representatives which shall
be approved by both parties prior to execution of the Agreement and/or the Sales Representatives going into a territory. Any fee to be charged by Ventiv to Iroko for the development and administration of a Compliance Monitoring Plan shall be
mutually agreed upon by the Parties. 

  
 *** Portions of this page
have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission. 

  
 Exhibit –
Page 5 

 APPENDIX A-1 
 MINIMUM TRAINING REQUIREMENTS 
 Ventiv shall provide initial training for all Ventiv Sales
Representatives spanning two weeks, including one week of home study to be followed immediately by one week of live training and encompassing at a minimum the following elements: 

 

									
	 HOME STUDY WEEK ONE
	 	  	 	 LIVE TRAINING WEEK TWO

	 •
  

 
  

•
  
 •
  
 •

 
 •
	 	 Scientific and Disease State Training in the area of Pain Management

 
 Iroko Product Training

 
 Competitor Training

 
 Iroko Selling Model

 
 Ventiv operations; Human Resources/Benefits, Fleet, Interplex, Sample
Accountability
	 		 	 •
  

•
  
 •
  
 •

 
 •

 
 •

 
 •

 
 •

 
 •
	 	 Iroko Product Message Training
  

Iroko Product Marketplace Training
  

Promotional Materials Training
  

Managed Markets Training
  
 Selling Skills Training
  

Selling Simulations Training
  
 Compliance Training
  
 Role
Playing Certifications (live and videotape)
  
 Sales Force Automation Tool
(SFA)

	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

  
 Exhibit –
Page 6 

 APPENDIX A-2 
 MEETINGS INCLUDED IN AGREEMENT 
 A. For Year One of the initial term of the
Agreement, the following meetings will be provided at Iroko’s expense: 
  

							
	 TYPE
	  	 RESPONSIBILITY
	  	 LENGTH
	  	 DATE

				
	Initial Training	  	Ventiv	  	2 weeks (one Homestudy and one Live)	  	TBD
				
	One National Launch Meeting	  	Iroko	  	3 days/3 nights	  	TBD
				
	Two Plan of Action Meetings	  	Iroko	  	2 days/one night each	  	TBD

 B. For Year Two of the initial term of this Agreement the following meetings will be provided at Iroko’s
expense: 
  

							
	TYPE	  	RESPONSIBILITY	  	LENGTH	  	DATE
				
	Initial Training	  	Ventiv	  	2 weeks (one Homestudy and one Live)	  	TBD
				
	Two Plan of Action Meetings	  	Iroko	  	2 days/one night each	  	TBD

  
 Exhibit –
Page 7 

 APPENDIX A-3 
 DATA MANAGEMENT/SALES REPORTS/ANALYSIS 
  

							
	 Items
	  	 Data / Function
	  	 Frequency
	  	 Base Assumptions

	1.  	  	Refresh Rx data in Veeva	  	Weekly	  	Split Weekly Prescriber Payer Rx data will be processed at ZS for Delivery to Ventiv
	2.  	  	Extract HCP Call Activity (HCP Sales Presentations & Samples)	  	Weekly	  	Iroko wants to have visibility into HCP activity frequently during launches.
	3.  	  	HCP – SFA transactions for: HCP Deletions, Merges and Additions as well as Address location and type changes.	  	Monthly	  	Ventiv / ZS and Iroko will need to discuss this category for agreement: TBD
	4.  	  	HCP Affiliation data exchanges	  	Monthly	  	Depending on Group Practice and other affiliation decisions. Ventiv/ZS and Iroko will need to discuss this for agreement
	5.  	  	Market Definition Changes	  	Monthly	  	 Monthly Changes at ZS – additional NDCs for existing molecules. Adds Rx count vs. new Product into a market definition.

 
 Quarterly (monthly on exception) Changes at ZS – New NDCs representing new
molecular entrants into a definition. Adds new Product and Rxs into a market definition.

	6.  	  	Alignment Changes – Any type of alignment (ZIP-Terr, HCP-Terr, HCO-Terr, Etc.)	  	Monthly	  	Discussion & agreement needed between Ventiv and Iroko to finalize
	7.  	  	Alignment Changes – COG to COG hierarchy changes.	  	Monthly	  	Discussion & agreement needed between Ventiv and Iroko to finalize
	8.  	  	Load new HCP Targeting and Segmentation Values	  	Monthly	  	
	9.  	  	Customer Call Planning and Attainment	  	Monthly	  	Iroko will work with Ventiv and ZS to evaluate options for delivering an optimal reporting/tracking solution including whether or not this can be delivered within SFA
environment.
	10.	  	Weekly and Monthly Sales and Activity Reports will be generated and delivered by ZS Associates.	  	Monthly	  	Iroko, Ventiv and ZS will have the opportunity to design sales and activity reports that will meet our needs.
	11.	  	IC Reporting (Goals, Eligibility, Progress, Payout)	  	Monthly	  	Details to be worked out with Ventiv
	12.	  	Extract Time Out of Territory data & generate standard (Administrative) reports.	  	Monthly	  	Details to be worked out with Ventiv

  
 Exhibit –
Page 8 

							
	 Items
	  	 Data / Function
	  	 Frequency
	  	 Base Assumptions

	13.	  	Reports to monitor the contractual performance of Ventiv to this Contract will be mutually defined at a later date.	  	Monthly	  	Details to be worked out with Ventiv
	14.	  	Refresh Formulary data in SFA (Fingertip, MediMedia, etc.)	  	Monthly	  	Details on business practices and exact data sources, metrics, views to be worked out with Ventiv and ZS.

  
 Exhibit –
Page 9 

 EXHIBIT B 
 COMPENSATION – FEES AND PASS-THROUGH COSTS 
  

	I.	FEES, SERVICES AND EXPENSES 

  

	 	A.	Implementation Fees 

 i)
Iroko shall pay Ventiv fixed fees associated with full performance of the Services and according to the following schedule: 
  

					
	 Fixed Implementation Fee
	  			
	 Initial IT Setup [***] Sales
	  			
	 Representatives*)
	  	 	[***	] 
	 Incremental IT Setup per Sales
	  			
	 Representative @ [***] per
	  			

  

			
	Project Team start dates:	  	
	National Business Director	  	[***] months prior to PDUFA date; Iroko billing
		  	begins [***] days prior to PDUFA date.
	Training Manager	  	[***] days prior to PDUFA date
	Employee Relations Managers	  	[***] days prior to PDUFA date
	Project Manager	  	[***] days prior to PDUFA date

 ii) Iroko shall also pay Ventiv a fixed implementation fee for each Sales Representative according to the
following schedule: 
  

									
	 Per Sales Representative
	  	Year 1	 	 	Year 2	 
			
	 Implementation
	  	 	[***	] 	 	 	[***	] 

 For the avoidance of doubt, there is no fixed implementation fee for members of the Project Team.

  

	 	B.	Fixed Monthly Fees 

 i) Iroko
shall pay Ventiv a Fixed Monthly Fee for Services as follows: 
  

									
	Per Sales Representative	  	Year 1	 	 	Year 2	 
	 Implementation
	  	 	$[***	] 	 	 	$[***	] 
	 Monthly Per Sales Representative
	  	 	$[***	] 	 	 	$[***	] 
	 Annually Per Sales Representative
	  	 	$[***	] 	 	 	$[***	] 
			
	Per ERM	  	Year 1	 	 	Year 2	 
			
	 Monthly Per ERM
	  	 	$[***	] 	 	 	$[***	] 
	 Annually Per ERM
	  	 	$[***	] 	 	 	$[***	] 

  
 *** Portions of this page
have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission. 

  
 Exhibit –
Page 10 

									
	Per NBD	  	Year 1	 	 	Year 2	 
	 Monthly Per NBD
	  	 	$[***	] 	 	 	$[***	] 
	 Annually Per NBD
	  	 	$[***	] 	 	 	$[***	] 
			
	Per Trainer	  	Year 1	 	 	Year 2	 
	 Monthly Per Trainer
	  	 	$[***	] 	 	 	$[***	] 
	 Annually Per Trainer
	  	 	$[***	] 	 	 	$[***	] 
			
	Per PM	  	Year 1	 	 	Year 2	 
	 Monthly Per PM
	  	 	$[***	] 	 	 	$[***	] 
	 Annually Per PM
	  	 	$[***	] 	 	 	$[***	] 

 The Implementation Fees, Services, and Pass-Through Costs set forth above are based upon the assumptions
set forth in the recruitment/training timeline agreed to by the Parties. In the event that the assumptions set forth in the recruitment/training timeline are changed, the Implementation Fee and/or Fixed Monthly Fee shall be re-calculated as
agreed-upon by the Parties. 
 [***] 
 D. Fee Reconciliation. The parties agree that the Fixed Monthly Fees set forth in Section B, above, are based on the average annual salary of $ [***] per Ventiv Sales Representative in Year One and
the average annual salary of $[***] per Ventiv Sales Representative in Year Two (the “Average Annual Salaries”). Ventiv and Iroko will reconcile actual salary, payroll taxes and any other related payroll expenses, excluding incentive
compensation, measured by actual days worked, for each Ventiv Sales Representative in such calendar quarter against an amount equal to the appropriate percentage of the Average Annual Salary. The parties agree that the Average Annual Salary does not
include bonuses for the Ventiv Sales Representatives (plus the applicable employer portion of taxes). If Ventiv’s actual annual salary per Ventiv Sales Representative is below the Average Annual Salary, then Ventiv shall issue a credit for the
entire amount of such difference to Iroko. If Ventiv’s actual salary per Ventiv Sales Representative is above the Average Annual Salary, then Ventiv shall bill the difference to Iroko. 

  
 *** Portions of this page
have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission. 

  
 Exhibit –
Page 11 

	 	E.	Management at Risk Fee: 

 i) Ventiv will accept a lesser fee or be entitled to a greater fee based on its results against certain sales and activity metrics to be agreed by the parties as set forth below. The amount of the greater
or lower fee will be determined by the amount of its fees Ventiv will put “at risk” (the “Metrics Pool”) against such metrics as follows: 
  

					
	 Per Sales Representative FTE:
	  	Added to the Metrics Pool	 
	 Fee At Risk (Monthly)
	  	 	[***	] 
	 Fee At Risk (Annually)
	  	 	[***	] 

 ii) The parties agree that Metrics Pool will be divided up against a combination of sales
and activity metrics as follows: 
  

													
	 Mgt Fee @ risk
	  	Months 1-6	 	 	Months 7-12	 	 	Months 13-24	 
	 Portion of Fee @ risk
	  	 	40	% 	 	 	40	% 	 	 	40	% 
	 Activity Based*
	  	 	100	% 	 	 	40	% 	 	 	40	% 
	 Sales Performance Based**
	  	 	0	% 	 	 	60	% 	 	 	60	% 

  

	 	•	 	 *activity based: example metrics to include % territories filled @ launch, all sales support services fully and successfully implemented to support
launch, Target Reach and Frequency objectives met, call plan adherence metrics achieved, program delivery objectives met. 

  

	 	•	 	 **performance based: example metrics starting month 7 to include sales goal achievement for ZORVOLEXTM @ end of Q2, Q3, Q4, sales goal achievement
for TIFORBEXTM @ end of Q2, Q3, Q4 

  

	 	•	 	 The Parties will meet and agree on the actual applicable metrics and the associated increase or decrease in Ventiv’s fees at least 60 days prior
to the anticipated Deployment Date. The Parties will meet and agree on Year 2 metrics at least 60 days prior to the start of Year 2. 

 iii) Example [illustrative only] percentages of Metrics Pool that could be earned by Ventiv based performance against the agreed metrics could be as follows: 

 

			
	Achievement % Against Metric	  	Payout % Earned by Ventiv
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]

 iv) Ventiv shall collect the Metric Pool as part of its Fees as otherwise set forth in
this Exhibit A and shall refund to Iroko any portion of the Metrics Pool which was unearned by Ventiv (i.e. for performance against a metric at less than 100%) within 

  
 *** Portions of this page
have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission. 

  
 Exhibit –
Page 12 

 
30 days of the determination of such. Iroko shall make any additional payments due Ventiv (i.e. for performance against a metric at greater than 100%) upon 30 days upon the determination that
such are due. 
 v) During Year One and Year Two, respectively, in the event of one of the following events, any
metrics based on the sales of the Products shall be paid at the greater of (y) 100% of sales target; or (z) the actual sales trend at the time of termination. The events are: (a) the FDA causes the withdrawal from the market of a
Product; (b) a Product incurs generic competition comprised of the same product characteristics and considered therapeutically equivalent and substitutable in the Territory; (c) a Product supply failure (excluding Samples) (i.e.,
Iroko is unable to provide a consistent supply of a Product to the market and such inability continues for a period of forty-five (45) days); or (d) Iroko no longer has rights to market, promote or sell a Product in the Territory during
the Term; or (e) a sample supply failure (i.e. Iroko is unable to provide a consistent supply of samples to the market and such inability continues for a period of greater than ninety (90) days.) 

 

	II.	PASS-THROUGH COSTS 

 In
addition to the Fixed Fees, certain expenses will be charged to Iroko on a pass-through basis. These expenses will be billed to Iroko at actual cost with no mark up. Pass-through costs include: 

Ventiv Sales Representative and Project Team “non-automobile” travel (including overnight travel) 

 

	 	•	 	 Costs for all meetings, including but not limited to POA Meetings 

 

	 	•	 	 Marketing and entertainment costs 

  

	 	•	 	 Sales TRx data and any third party data 

  

	 	•	 	 Ventiv Sales Representative product storage units 

  

	 	•	 	 Turnover recruitment and training 

  

	 	•	 	 Tolls and parking 

  

	 	•	 	 Office supplies 

  

	 	•	 	 Direct marketing customer funds 

  

	 	•	 	 Licensing and credentialing of Ventiv Sales Representatives 

 

	 	•	 	 Interview expenses 

  

	 	•	 	 Sales Representative bonus and applicable portion of employer taxes 

 

	III.	MISCELLANEOUS FEES AND CREDITS 

 A. Ventiv Incentive Compensation Plan. Provided the Year Two incentive compensation plan remains consistent with the Year One incentive compensation plan, Iroko shall pay Ventiv $10,000 (in Year
Two and in the first extension term beyond Year Two) for the continuing administration and maintenance of the incentive compensation plan. This fee shall be paid within thirty (30) days of the commencement of each such year. There shall be no
cost for the initial design, program and administration of the incentive compensation plan for members of the Project Team in Year One. 

  
 Exhibit –
Page 13 

	 	B.	State License Validation Fees. 

 Iroko shall pay Ventiv a one-time set up fee of $1,000 and a per-lookup fee in accordance with the following, if and when these services are required: 

 

					
	PERIOD	  	AUTOMATED LOOKUP	  	MANUAL LOOKUP
			
	 Year One
	  	$.60 per lookup	  	$1.20 per lookup
			
	 Year Two
	  	$.63 per lookup	  	$1.26 per lookup
			
	 Year Three
	  	$.66 per lookup	  	$1.32 per lookup

 [***] 

  
 *** Portions of this page
have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission. 

  
 Exhibit –
Page 14 

 [***] 
 E. Effect of Product Non-Approval. In the event the Product is not approved by the FDA and Iroko therefore does not deploy the Sales Representatives, then Iroko shall make a one-time payment to
Ventiv in the amount equal to $26,905 times the number of months from the National Business Director’s start date and the date Iroko notifies Ventiv that the services of the National Business Director are no longer needed. Nothing in this
provision shall be read to grant rights not otherwise contained in this Agreement. 
  

	IV.	INVOICES; BILLING TERMS 

The Implementation Fee shall be paid by Iroko to Ventiv on the Recruitment Start Date and one month of Fixed Monthly fee shall be paid by
Iroko to Ventiv after PDUFA and before Sales Representative Start Date. Commencing on the Sales Representative Start Date, Iroko will be billed monthly in advance the amount stated above as the Fixed Monthly Fee. Pass-through Costs will be billed to
Iroko at actual cost as incurred by Ventiv. 
 Invoices are due thirty (30) days from invoice date. If not paid within 30
days of date of invoice, Ventiv reserves the right to impose a finance charge of 1.5% monthly, applied to the outstanding balance due. 

  
 *** Portions of this page
have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission. 

  
 Exhibit –
Page 15 

 EXHIBIT C 
 SAMPLING AND SAMPLE ACCOUNTABILITY 
 POLICIES AND PROCEDURES

 General 
 Ventiv, acting
as a contract sales organization on Iroko’s behalf and authorized distributor of Iroko’s Product samples, shall utilize a prescription drug sampling program (the “Sampling Program”) for the sampling of Iroko’s Products by
Ventiv Sales Representatives. The Sampling Program shall comply in all respects with applicable Federal and State laws and regulations, including but not limited to the Federal Prescription Drug Marketing Act of 1987, as amended (“PDMA”)
and the regulations and guidelines promulgated thereunder. The Parties will reasonably cooperate from time to time to the extent necessary to ensure compliance with the applicable legal and regulatory requirements. 

Responsibility for Sample Shipment, Distribution and Storage 
 The Sampling Program provides for the shipment of Product samples by Iroko to a Ventiv storage and distribution facility. Ventiv shall be responsible for storage of the Product Samples under appropriate
GMP and PDMA conditions and distributing the Product samples directly to the Ventiv Sales Representatives in accordance with the Iroko Sampling Plan. Ventiv shall be responsible for distribution in accordance with applicable legal requirements,
including, without limitation, the PDMA. Ventiv Sales Representatives shall be responsible for appropriate receipt, handling and storage of Iroko’s samples including maintaining appropriate security while in their possession. Iroko shall assume
the risk of loss with respect to Product samples during shipment to the Ventiv distribution facility. Upon arrival of the product samples at the Ventiv distribution site, Ventiv personnel will verify the quality and number of the contents, any
discrepancy will be reported immediately to Iroko (within 24 hours) and investigated by both parties. Once verification of the quality and content of the product samples is established, Ventiv shall take responsibility for the product sample for the
purpose of shipping to Ventiv Sales Representatives. Any loss during storage or transit that occurs from the shipments out of the Ventiv’s distribution facility will be the responsibility of Ventiv for the purposes of investigations and
reporting to Iroko. 
 Sampling of Practitioners 
 Iroko shall follow Ventiv’s policies and procedures as they relate to sampling of validated physicians. These guidelines will be established through the client business rules. Ventiv shall conduct a
prescriber validation of State License information for the lists of Prescribers utilized by the Ventiv Sales Representatives for the fees stated herein. Ventiv Sales Representatives shall follow Iroko’s Sampling Plan guidance with respect to
the sampling of validated physicians. 

  
 Exhibit –
Page 16 

 Sample Accountability Records 
 Ventiv shall design and implement a security and audit program that includes allowance for random, for cause and periodic audits to include physical inventories of Product samples delivered to the Ventiv
Sales Representatives consistent with the PDMA and applicable regulations. Ventiv will generate inventory records, reconciliation reports and summary reports as required by the FDA regulations and other applicable Federal and State laws and
regulations including but not limited to the Patient Protection and Affordable Care Act (Section 6004 – Prescription Drug Sample Transparency) and regulations promulgated in related thereto, and all such reports shall be in a format that
enables Iroko to comply with such legal requirements. 
 If Ventiv utilizes any electronic record-keeping systems, it represents that such
systems are compliant with 21 CFR Part 11 and that if the system(s) allow for partial electronic record-keeping and part paper record-keeping, (1) there is a reasonably secure link between paper-based and electronic records; and (2) the
link ensures that the records are reliable and that the signer cannot readily repudiate the signed records as not genuine. Ventiv further represents that all records are maintained in a form that provides reasonable assurance of being
(1) tamper-resistance; (2) accessible and retrievable; and (3) available for reproduction or copying. 
 Written
Accountability Policies and Procedures 
 Ventiv will prepare written policies and procedures as required under FDA regulations and
applicable Federal and State laws, and provide training and instruction to Ventiv Sales Representatives on the policies and procedures. The written policies and procedures will address: (i) the inventory process and preparation of the
reconciliation report, (ii) an inventory schedule and reconciliation schedule, (iii) the audit standards for detecting falsified and incomplete records and sample loss and/or theft, including but not limited to random and for-cause audits
of Ventiv Sales Representatives by personnel independent of the sales force, (iv) what is a significant loss and how it is to be identified, (v) responsibility for notifying the FDA, (vi) system for monitoring samples to identify the
loss or theft of samples, including request and receipt form reconciliation, identification of patterns of nonresponse, and responses when such patterns are discovered, (vii) the standards for storage of samples, and (viii) standards and
procedures for Ventiv Sales Representative sample compliance training, including but not limited to applicable PDMA requirements. Ventiv shall make available to Iroko from time to time as reasonably requested by Iroko a written copy of Ventiv’s
written policies and procedures. 
 Ventiv shall provide written policies and procedures for the distribution of Product samples to Ventiv Sales
Representatives. These procedures shall include the process for return of unused samples and relevant procedures for destruction of samples. 

Audit Services 
 Under the Sampling
Program, Ventiv will develop audit procedures including random selection audits, operational guidelines, proposed timeliness and checklists to demonstrate PDMA compliance to performance requirements regarding security functions. These procedures
will 

  
 Exhibit –
Page 17 

 
include random and for-cause audit criteria, on-site inventory, inspection of sample storage locations, interviews of Ventiv Sales Representatives and reconciliation services and reports. The
on-site inventory of the samples in the possession of a Ventiv Sales Representative and related reconciliation services and report shall constitute a “physical audit”. In addition to any other physical audits, performed by Ventiv, required
by the PDMA and/or regulations thereunder and/or by other related Federal or State laws and/or the applicable written policies and procedures for the Sampling Program, a physical audit shall be conducted on each Ventiv Sales Representative upon
termination of the Agreement, or termination of employment by Ventiv or reassignment from Iroko’s project during the Term of the Agreement. Random practitioner signature audits will be performed by Ventiv on an at least an annual basis, and on
a for-cause basis as requested and/or determined by Iroko, with the results reported to Iroko. 
 Shipment of Samples 

Ventiv shall distribute Product samples directly to the Ventiv Sales Representatives. Ventiv shall be responsible for those shipments, including using
appropriate delivery verification and confirmation systems and documentation. Ventiv shall provide Iroko with a written description of that delivery verification system. Ventiv shall provide Iroko with all PDMA-related information concerning shipped
samples as required by FDA regulations (including lot numbers). This information will be delivered utilizing the existing shipment and returns electronic file that is currently produced on a daily basis and processed by Ventiv. Ventiv shall also
provide all information reasonably necessary to allow Ventiv Sales Representatives to verify the receipt of shipped samples. 
 Ventiv Sales
Representatives will utilize a sales force automation system, which Ventiv represents adheres to 21 CFR Part 11, to acknowledge delivery of samples which will allow Ventiv to confirm shipments of samples by Ventiv to the Ventiv Sales
Representatives. Ventiv will reconcile the receipt of samples by each Ventiv Sales Representative with the samples shipped to such person, based upon the shipping records provided to it and acknowledgement of delivery provided by the Ventiv Sales
Representatives. All discrepancies between the sample shipping records and the acknowledgment of delivery by the Ventiv Sales Representatives shall be identified by Ventiv and reported to Iroko within five (5) days of discovery and in
compliance with all applicable reporting requirements. All significant losses or thefts or the potential for significant loss or theft of samples shall be investigated and the results of the investigation shall be reported by Ventiv to Iroko within
twenty (20) days of opening the investigation or sooner if required for Iroko to comply with applicable State requirements. To the extent Ventiv uses a third party vendor to provide any shipping and/or delivery verification services, Ventiv
shall ensure that the third party vendor is compliant with all applicable Federal and State laws, including the PDMA and the regulations of the FDA. 
 Returns 
 Ventiv shall be responsible for providing a procedure for Ventiv Sales
Representatives to return Product samples and correspondingly providing Iroko with a copy of the Policies and Procedures for the appropriate disposal and destruction of the returned Product Samples. Ventiv will confirm all returns of samples by the
Ventiv Sales Representatives. Ventiv will provide a report 

  
 Exhibit –
Page 18 

 
of sample returns on a weekly basis and make readily available to Iroko as requested. Ventiv shall not remove, destroy or otherwise impair the availability of the returned samples until
identified discrepancies of returned quantities have been resolved by Ventiv. 
 Access to Records 

Ventiv shall provide Iroko access and opportunity to inspect all documents, records and inventory required to be kept under the Sampling Program within
twenty-four (24) hours of a written or verbal request by Iroko. 
 Notification of Iroko; of FDA 

Upon Ventiv’s discovery that any Product samples have been lost or stolen, Ventiv shall, within twenty-four (24) hours, report such theft or
loss to Iroko. Ventiv shall determine, in a time frame dictated by Federal and/or applicable State requirements, whether a “theft” or a “significant loss” has occurred under the PDMA and the FDA regulations and applicable State
requirements after reviewing all applicable information with regard to such samples. Ventiv will also be responsible for determining whether there is “reason to believe” that a diversion of a sample or falsification of a sample record by a
Ventiv Sales Representative has occurred. This would include, but is not limited to, patterns of discrepancies or whether reliable information indicates that records have been falsified. Ventiv shall notify Iroko within twenty-four (24) hours
of determining that there is “reason to believe” that a diversion or falsification has occurred, so that Iroko can report the situation, if applicable, as required to FDA and applicable State authorities. 

In both situations, referenced above, Ventiv will immediately initiate an investigation, fully cooperate with Iroko with its investigation efforts, as
applicable, and provide Iroko with all applicable information, including a written report if requested by Iroko, within twenty (20) days of the date of Ventiv’s initial notification to Iroko, or sooner if required by applicable State or
Federal requirements, or if specifically requested by Iroko in connection with an ongoing compliance investigation, so that Iroko can submit all required follow-up reports and take any and all actions required by the FDA or any other governmental or
regulatory agency. 
 Ventiv shall also report to Iroko within five (5) business days of becoming aware of the conviction of one of its
Sales Representatives for a violation of the PDMA requirements or any related Federal or State law involving the sale, purchase or trade of a drug sample or the offer to sell, purchase or trade a drug sample. 

Prescription Sample Identification 

Iroko shall notify Ventiv of the lot numbers of samples being shipped by Iroko to Ventiv storage facilities in advance of shipment. Ventiv shall require
that the Ventiv Sales Representatives keep records by lot number of all samples distributed to licensed practitioners. Ventiv will reconcile sample data according to product code. 

  
 Exhibit –
Page 19 

 Recalls 
 The Parties will maintain such traceability records as may be necessary to permit a recall or field correction of the Products. The decision to conduct and the right to control a recall shall be solely
Iroko’s. Ventiv shall cooperate fully with Iroko in connection with any recall efforts affecting the Product. 
 Accountability Training

 The Parties recognize that the Sampling Program will require incremental training in sample accountability. Ventiv will
provide all Ventiv Sales Representatives with training which addresses sampling requirements and which Iroko shall have the opportunity to review in advance. Ventiv agrees to implement reasonable upgrades or revisions to the sample accountability
training requested by Iroko. Ventiv will consult with Iroko to assure that the Ventiv Sales Representatives will use detail bags and report forms which are acceptable to Iroko. Ventiv will be responsible far any follow-on training or corrective
action training. 
 Iroko Sampling Plan 
 Iroko shall provide Ventiv with a Sampling Plan that provides appropriate guidance as to the distribution of Product Samples to validated physicians at least 30 days in advance of each quarterly Plan of
Action promotional cycle, Iroko’s Sampling Plan will provide guidance as to the amount of Product Samples to be distributed to each Sales Representative as well as providing guidance as to the number of Product Samples to be distributed to
individual physicians based on their segment profile. Any variance to guidelines relating to the number of Product Samples to be distributed to individual physicians will require approval by the Iroko Regional Business Managers. 

Reports 
 Ventiv shall provide the following
standard reports to Iroko during the term of this Agreement. 
  

			
	 Report Name
	  	 Description

		
	Missing Inventory Report	  	List all active Sales Representatives who failed to submit an inventory for a specified inventory schedule
		
	Quantity On Hand Report	  	List all the products in Sales Representative’s possession as of run date based on the transactions received. The report will only include active Sales
Representatives.
		
	Error Code Report	  	Shows the number of open errors each Sales Representative has for each exception code. This is only generated for active
Representatives.

  
 Exhibit –
Page 20 

			
		
	Activity Report – By Date	  	 There are 2 kinds of reports; 1. Report on the number of disbursement forms that were scanned each day for each active Sales
Representative.
  
 2. Report on the number of Calls made by each active Sales
Representative each day. Both paper and electronic documents are included in the count. When paper and electronic documents are linked together, it is counted once only.

		
	Activity Report – By Week	  	 There are 2 kinds of reports; 1. Report on the number of disbursement forms that were scanned each week for each active Sales
Representative.
  
 2. Report on the number of Calls made by each active Sales
Representative each week. Both paper and electronic documents are included in the count. When paper and electronic documents are linked together, it is counted once only.

		
	Activity Report – By Month	  	There are 2 kinds of reports; 1. Report on the number of disbursement forms that were scanned each month for each active Sales Representative. 2. Report on the number of Calls made
by each active Sales Representative each month. Both paper and electronic documents are included in the count. When paper and electronic documents are linked together, it is counted once only.
		
	Missing Closeout Report	  	This report shows the list of terminated Sale Representatives who failed to submit a closeout inventory.
		
	Invalid Lot Report	  	This report shows the list disbursement forms that contain invalid lot numbers. Valid lot numbers are based on the lots listed on PRODUCT LOT.
		
	Expired / Short Dated Lot Report	  	This report shows all the products that are in the Sales Representative’s possession that are already expired or are expiring in X number of days.
		
	SIRR Report	  	The Standard Inventory Reconciliation Report (SIRR) generates a separate reconciliation report for each individual Sales Representative from the selected reconciliation list. The
Reconciliation Report reconciles a Sales Representative’s sample activity and transactions between two scheduled inventories using the starting Corporate and Sales Representative inventory counts, then applying the sample activity and
transactions during this period to calculate the ending Corporate inventory and comparing it to the on-hand quantities from the Sales Representative’s ending inventory for that period, showing any product variances.
		
	Inventory List Report	  	Shows all the inventories submitted by the Sales Representative between 2 inventory periods.
		
	Standard Reconciliation	  	The Standard Reconciliation Report generates either an employee reconciliation report or a corporate reconciliation report. The report will contain summary or summary and detail in
one report. The Reconciliation Report reconciles a Sales Representative’s sample activity and transactions between two scheduled inventories using the starting Corporate and Sales Representative inventory counts, then applying the sample
activity and transactions during this period to calculate the ending Corporate inventory and comparing it to the on-hand quantities from the Sales Representative’s ending inventory for that period, showing any product
variances.
		
	Compliance Dashboard Report	  	The Compliance Dashboard is a report that highlights the Sales Representative whenever compliance related situation arise. It is extremely useful for monitoring the agent’s
behavior and patterns.
		
	Linking Report – ACK missing Shipment	  	Shows all shipments acknowledged by the Sales Representative that is not linked to the shipment records received from the
warehouse/shipper.

  
 Exhibit –
Page 21 

			
		
	Linking Report – ACK missing Return	  	Shows all corporate returns that are not linked to field returns.
		
	Linking Report – Disbursement missing SFA	  	Shows all paper calls received that are not linked to an electronic call. This is applicable to clients that use SFA.
		
	Linking Report – Disbursement missing Paper	  	Shows all electronic calls received that are not linked to a paper call. This is applicable to clients that use SFA.
		
	Linking Report – TI missing TO	  	Shows all transfer IN calls received that are not linked to a transfer OUT record.
		
	Linking Report – Shipment missing ACK	  	Shows all shipments that have not been acknowledged by the agents.
		
	Linking Report – Return missing ACK	  	Shows all returns that have not been acknowledged by the shipper/warehouse.
		
	Linking Report – TO missing TI	  	Shows all transfer outs that have not been acknowledged receiving Sales Representative.
		
	Linking Report – Discrepant Shipments	  	Shows all shipments that are linked to the shipment acknowledgement but some details do not match.
		
	Linking Report – Discrepant Returns	  	Shows all Field Returns that are linked to the Corporate Return but some details do not match.
		
	Linking Report – Discrepant Transfers	  	Shows all Transfers that are linked together but some details do not match.
		
	Linking Report – Discrepant Disbursements	  	Shows all disbursements that are linked together but some details do not match.
		
	QOH Summary Report	  	Shows the total quantity on hand across all employees per product. Calculation starts from the last submitted inventory plus/minus transactions thereafter.
		
	Storage Report	  	Shows the storage location addresses for each agent.

 The following reports are available in the ‘Transaction Link’ submenu of the ‘Transaction’ tab
in SIMS: 
  

			
	 Report Name
	  	 Description

		
	ACK – Missing Shipment	  	Shows all shipments acknowledged by the Sales Representative that is not Linked to the shipment records received from the warehouse/shipper.
		
	ACK – Missing Return	  	Shows all corporate returns that are not linked to field returns.
		
	Disbursement – Missing SFA	  	Shows all paper calls received that are not linked to an electronic call. This is applicable to clients that use SFA.
		
	Disbursement – Missing	  	Shows all electronic calls received that are not linked to a paper call. This is applicable to clients that use
SFA.

  
 Exhibit –
Page 22 

			
		
	Transfer IN – Missing Transfer OUT	  	Shows all transfer IN calls received that are not linked to a transfer OUT record.
		
	Shipment – Missing ACK	  	Shows all shipments that have not been acknowledged by the agents.
		
	Return – Missing ACK	  	Shows all returns that have not been acknowledged by the shipper/warehouse.
		
	Transfer OUT – Missing Transfer IN	  	Shows all transfer outs that have not been acknowledged by receiving Sales Representative.
		
	Shipment – Discrepant	  	Shows all shipments that are linked to the shipment acknowledgement but some details do not match.
		
	Return – Discrepant	  	Shows all Field Returns that are linked to the Corporate Return but some details do not match.
		
	Transfer – Discrepant	  	Shows all Transfers that are linked together but some details do not match.
		
	Disbursement – Discrepant	  	Shows all disbursements that are linked together but some details do not match.

 The following reports are available in the ‘Reconciliation’ submenu of the ‘Recon’ tab in SIMS:

  

			
	 Report Name
	  	 Description

		
	Variance Report	  	This report shows the difference between the inventory counts submitted by the Sales Representative and the calculated ending corporate inventory.
		
	Corporate SIRR	  	Shows the entire product inventory then applying the sample activity and transactions during this period to calculate the ending corporate inventory and comparing it to the on-hand
quantities from the Sales Representative’s ending inventory for that period.
		
	Sales Representative SIRR	  	Shows the Sales Representative starting inventory per product then applying the sample activity and transactions during this period to calculate the ending expected inventory and
comparing it to the on-hand quantities from the Sales Representative’s ending inventory for that period, showing any product variances.
		
	QOH Detail	  	Shows the total quantity of all products per employee. Calculation starts from the last submitted inventory plus/minus transactions thereafter.
		
	Comment	  	List all the comments used for reconciliation.

 The following reports are available in the ‘Ad Hoc Report’ submenu of the ‘Report’ tab in SIMS:

  

			
	 Report Name
	  	 Description

		
	Adjustment Comparison Report	  	List all manual adjustment per employee per product showing the call original data and call adjustment data.
		
	Manual Adjustment Comment	  	List all manual quantity adjustment per Sales Representative per product showing the reason of adjustment.
		
	Paper No SFA Report	  	Shows all paper calls received that are not linked to an electronic call. This is applicable to clients that use
SFA.

  
 Exhibit –
Page 23 

			
		
	Paper SFA Difference Report	  	List all paper calls only or SFA calls only.
		
	SFA No Paper Report	  	Shows all electronic calls received that are not linked to a paper call. This is applicable to clients that use SFA.
		
	Call Card Usage Report	  	List all call sampling usage.
		
	Disbursement – Exception Count By Code	  	Lists all exception code.
		
	Disbursement – Exception Count By Sales Representative	  	List all exception code per Sales Representative.
		
	Disbursement – Exception Count By Sales Representative Details	  	Lists all exception code per Sales Representative call details.
		
	Inventory And Sampling Count	  	List all inventory and call sampling activity side by side.
		
	Practitioner Exceed Max Month Quantity	  	List all practitioners that exceed maximum quantity per product.
		
	Sampling By Area	  	List all products sampling activity by area.
		
	Sampling By District	  	List all products sampling activity by district.
		
	Sampling By Sales Representative	  	List all product sampling activity by Sales Representative.

  
 Exhibit –
Page 24 

 EXHIBIT D 
 ADDITIONAL SALES REPRESENTATIVE(S) REQUEST FORM 
 This Request for Additional Sales
Representative(s) is issued pursuant to the Master Services Agreement between Client and Ventiv Commercial Services, LLC, dated                    
and the Project Agreement issued thereunder dated                     . 

 

							
	PART 1	 		 	 To be completed by Client
 Attach any relevant, helpful information

	NUMBER OF SALES REPRESENTATIVE(S) REQUESTED	 		 		 	
				
	TERRITORY LOCATION(S)	 		 		 	
				
	REQUESTED START DATE	 		 		 	
				
	 AUTHORIZED CLIENT REPRESENTATIVE

SUBMITTING REQUEST
	 		 	 Signature:
 Name:

Title:
 Date:

Phone:
 Fax:
	 	  

			
	PART 2	 		 	To Be Completed by Ventiv
			
	 NEW SALES REPRESENTATIVE DETAILS:
  

Implementation Fee $        
 Added Fixed Monthly Fee: $        
	 		 	 Request is Accepted, and Recruitment shall begin immediately upon Client approval of New Sales Representative
Details:
  
  

	Target Representative Start Date:                     	 		 	 (sign and date)

Ventiv Contact Person:

Phone:

			
		 		 	New Sale Representative Details accepted and customer understands that recruiting will begin immediately:
		 		 	  

 

		 		 	 (sign and date)

Client Contact Person:

Phone:

  
 Exhibit –
Page 25

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00218-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00218-of-00352.parquet"}]]